CA1304135C - Patient-operated glucose monitor and diabetes management system - Google Patents

Patient-operated glucose monitor and diabetes management system

Info

Publication number
CA1304135C
CA1304135C CA000537188A CA537188A CA1304135C CA 1304135 C CA1304135 C CA 1304135C CA 000537188 A CA000537188 A CA 000537188A CA 537188 A CA537188 A CA 537188A CA 1304135 C CA1304135 C CA 1304135C
Authority
CA
Canada
Prior art keywords
patient
data
monitor
insulin
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000537188A
Other languages
French (fr)
Inventor
Lyle M. Allen, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZyCare Inc
Original Assignee
ZyCare Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZyCare Inc filed Critical ZyCare Inc
Application granted granted Critical
Publication of CA1304135C publication Critical patent/CA1304135C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0295Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/30ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/92Computer assisted medical diagnostics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Emergency Medicine (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

PATIENT-OPERATED GLUCOSE MONITOR
AND DIABETES MANAGEMENT SYSTEM
Abstract A monitor system is provided which includes means for measuring blood glucose values and for generating glucose data signals, monitor means coupled to the measuring means and including means for inputting patient data, means for transmitting and receiving data to and from the monitor means, and computing means for receiving glucose data signal in connection with admi-nistration treatment for diabetes mellitus.

Description

~L3`~L3~

PATIE~T-OPERATED GLUCOSE MONITOR A~D
DI~BETES I~ANAGEME~T SYSTE~
Background of the Invention The present invention relates` to a home moni-toring system including a computer assisted reflectance photometer designed for measuring blood glucose values at home, and for storing and transmitting these and other data to a physician in connection with administra-tion of treatment for diabetes mellitus.
In recent years there has been an enormous growth o~ monitoring blood glucose in the home. It has recently been estimated that 8% of the 5 million Americans currently diagnosed as suffering from diabetes mellitus monitor blood glucose at home.
Home glucose monitoring is an attempt to insti-tute cybernetic control in the management of diabetes.
In theory, patients monitor their blood glucose multiple times a day and record this information in log books.
The information is then used by the patient's physician to periodically adjust the dosage of insulin or other therapeutic agent. Sometimes, the insulin-taking patient is given an algorithm to make insulin adjustments himself based on the data he collects.
In order for home glucose monitoring to impact significantly on the treatment of a given patient, one must assume that (1) the patient monitors home glucose \

~3~

as prescribed using correct techniques, (2) the patient records values reliably in a log boo~, ~3) the patient comes to the physician's offices periodically to review his or her data, (4) the physician is able to make treatment recommendations based on viewing this data, and (5) the patient is in some cases able to adjust his or her own insulin based on this data.
These assumptions, however, frequently do not hold in practice. Patients often forget to monitor their glucose at the appropriate time; or, when they do, they often use poor technique, making the values unre-liable. Data may not be recorded properly in log books.
Even when data is properly collected and recorded, most physicians cannot make intelligent treatment decisions by reviewing pages of raw data. Finally, insulin adjustment by the patient using data gathered from home glucose monitoring applied to an algorithm i9 a process too complicated for most patients to follow.
Objects and Summary of the Invention An object of the present invention is to provide an apparatus for accurately recording blood glucose data and other relevant treatment values.
Another ob~ect of the invention is to provide an apparatus for processing patient glucose data values in terms of a physician-prescribed algorithm.
An additional object is the provision of appara-tus for transferring a patient's blood glucose data values over a communications channel to a physician's base computer station.
A further object of the invention is to provide a simpler, more reliable blood glucose monitoring system.
According to the present invention, as embodied and broadly described herein, a monitor is provided comprising, in combin~tion, a reflectance photometer for measuring blood glucose levels, a circuit coupled to the reflectance photometer for converting the output from the reflectance photometex to a glucose data signal, and monitor means coupled to S the circuit for storing the glucose data signal. The present invention also provides as part of the monitor means apparatus for inputting administered insulin data and means for comparing glucose data with the adminis-tered insulin data, and other data (stress, exercise, dietary intake) and outputting a recommended insulin dose based on a physician-prescribed algorithm in response to the comparison. The circuit comprises an analog-to-digi.tal converter coupled to the glucose reflectance photometer for generating the glucose data signal, and a data multiplexer coupled to the output of the analog-to-digital converter and having an output coupled to the monitor means, for controlling the transfer of signals between the analog-to-digital converter and the monitor means.
In accordance with another aspact of the invention there is provided a monitor system adapted for use by a patient afflicted with diabetes mellitus comprising means for measuring blood glucose values and for generating blood glucose data in response to measuring the blood glucose values, and monitor means connected to the measuring means and capable of receiving, storing and evaluating data for receiving and storing the blood glucose data, for receiving and storing physician-supplied data, for prompting and receiving patient input into the monitor means at periodic times of patient data relating to diet, exercise, emotional stress and symptoms of hypoglycemia and other illness experienced by the patient during a preceding time period, for receiving and storing the patient data supplied by the patient, and for generating recommendations relative to patient insulin dosage based at least in part upon the received blood glucose data, physician data and patient data.
Pursuant to still another aspect of the invention there is provided a monitor system comprising means for measuring blood glucose levels and for generating glucose data signals in response to the measurements. The invention further includes monitor means !~

coupled to the measuring means and including means for i.nputting patient data, means for transmitting and receiving data to and from the monitor ~eans, means for storing physician prescription data, glucose data signals and the patient data, and means for generating at least one recommended prescribed insulin dose in response to evaluating the stored glucose data signals, patient data and physician data. Further, the system of the invention includes computing means for receiving glucose data signals and storing patient data from the monitor, for evaluating the data according to a physician-prescribed algorithm and adjusting a physician insulin prescription in response to the evaluation, and for transmitting the physician insulin prescription to the monitor.
The invention also includes the inventive method for ~-5 monitoring diabetes mellitus having a monitor apparatus storing physician assessment parameters and prescription data, a blood glucose measuring device coupled to the monitor apparatus, a computer located remotely from the monitor apparatus and connected thereto over a communication channel. The diabetes monitoring method comprises the steps of measuring blood glucose va~ues with the blood glucose measuring device, storing the blood glucose values as glucose data in the monitor apparatus, inputting patient data into the monitor apparatus, sending the glucose data and patient data to the computer over the communication channel, evaluating the glucose data and patient data with the computer and transmitting to the monitor the physician assessment parameters, storing the physician assessment parameters in the monitor apparatus, and using the monitor apparatus to generate insulin dosage recommendations based upon the therein stored physician assessment parameters, glucose data and patient data.
In a further embodiment the invention provides a method of monitoring a patient having diabetes mellitus with the use o~ a blood glucose measuring device and a thereto linked monitor apparatus capable of receiving and storing data, and of using the data to generate insulin dosage recommendations which comprises inputting initial physician-supplied data into the monitor apparatus, supplying patient blood specimens at periodic times to i, i .

3~
-~a-the measuring device utilizing the measuring device to obtain blood glucose values from -the specimens, and -to effect automatic input into the monitor apparatus of glucose data representative of the glucose values, utilizing the monitor apparatus to prompt and S receive patient input into the monitor apparatus at periodic regular times of patient data relating to diet, exercise, emotional stress, and symptoms of hypoglycemia and other illness actually experienced by the patient during a preceding time period, storing in the monitor apparatus the inputted physician, glucose and patient data, and utilizing the monitor apparatus to at times evaluate the data stored therein and to generate recommendations, based upon the evaluation, relative to patient insulin dosage.
Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention.
Brief Description of the Drawings ~he accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate a preferred embodiment of the invention and, together with the description, serve to explain the principles of the invention.
Fig. 1 depicts the monitor apparatus and illustrates its display, glucose reflec-tometer strip guide, and input key switches.
Fig. 2 is a system-level schematic diagram illustrating the monitor system of the invention.
Fig. 3 is a detailed schematic diagram of the elements connected to the I/O control circuit shown in Fig. 2.

~3~ '2S

Fig. 4 is a system ]evel diagram illustrating the physician/patient relationship based on use of a monitor system employing a modem for communicating with a physician base station; shown with Fig. 1.
Fig. 5A is a functional flow chart illustrating the hypoglycemic symptom assessment firmware module employed in the monitor apparatus.
Fig. 5B is a functional flow chart illustrating the blood glucose assessment firmware module.
Fig. 5C is a functional flow chart illustrating the exercise assessment firmware module, emotional stress assessment firmware module, and illness assessment firmware module.
Fig. 5D is a functional flow chart illustrating the dietary assessment firmware module.
Fig. 5E is a functional flow chart illustrating the body weight recording firmware module.
Fig. 5F is a functional flow chart illustrating the diet, exercise, stress, illness (DESI) data eva-luation firmware module.
Fig. 5G is a functional flow chart illustrating the sequence of the insulin supplementation, basal insu-lin adjustment, and insulin recording/administration firmware modules.
Figs. 6A-6C taken together, are a functional.
flow chart diagram of the supplemental insulin adjust-ment firmware module.
Figs. 7A-7H taken together, are a functional flow chart diagram of the base insulin adjustment firm-ware module.
Figs. 8A-8F ta~en together, are a functional flow chart diagram of the insulin recording/administra-tion firmware module~ Figs. 8B-8D in particular, illustrate a subfunction of the recording/administration ~3~

modu:Le for computing the current insulin dose. Figs.
8E-8F illustrate another sub-function of the recording/
administration module for checking the patient's data entry o~ insulin taken.
Detailed Description of the Preferred Embodiment Reference will now be made in detail to the pre-sent preferred embodiments of the invention, examples of which are illustrated in the accompanying drawings.
In Fig. 1 a monitor unit 10 is shown including a keyboard 11, a light emitting diode (LED) display 12 and a glucose reflectometer strip guide 14. The keyboard has a plurality of keys as follows. The "ON" key is pressed to turn the monitor on. ~he "SE" key (Schedule Entry) is pressed to begin performing a scheduled blood test and/or insulin injection and to log behavioral data. "U~" (UNscheduled entry) is pressed to begin per-forming an unscheduled or "extra" blood test or insulin injection. "RD" ~Review Data) is pressed to look at data from previous blood tests or insulin injections.
After each blood test, the monitor will auto~atically provide the previous 3-day blood sugar average for the relative time of day. If desired, the actual numbers for each day can be displayed using the RD key. ~he "X"
(special functions) key controls transmission of data, changing the speed of the ~isplay, changing the monitor clock, and changing the monitor alarm. The "C~NCEL" key is pressed whenever a data entry error is made so that the monitor is returned to the beginning of a procedure to allow reentry of data.
Number keys 0, 1, 2, 3, etc., are used to enter information into the monitor, for example, weight, dietary intake, etc. The "ENTER" key is used after operation of a series of number keys and unctions to enter the data into the system. ENTER also indicates ~3~

"proceed to the next step." ENTER is used only when entering numbers to record weight, blood sug~r, calories, food exchanges, doctor appointment dates, insulin doses or other medications. Whenever <E>
appears on the display screen of the monitor the ENTER
key must be pressed following the numbers. The ENTER
key is not needea when recording data relating to exer-cise, emotional stress, urine ketone levels or food intake, which all use a ~ 5" scale.
At times the monitor will sequence a patient through a task, such as performing a finger prick, or will pause for the patient to think about the infor-mation which is displayed on a monitor screen. When the patient has finished a particular procedure, or the patient is ready to proceed to the next step, the patient must press the ENTER key to signal the monitor the patient is ready. Whenever the patient sees the <E>
on the display screen, the patient must press the ENTER
key to proceed.
"CLEAR" is pressed to clear the numbers which have been entered incorrectly, but before the ENTER key has been pressed. This allows a correction if the wrong numbers have been pressed for such items as weight, blood sugar, calories or insulin dose. This key cannot be used after pressing a number for exercise, emotional stress, food intake, or any item measured with a "1-5"
or other menu type scale. The upwards arrow (~) and downwards arrow (O keys indicate upward and downward movement of the display. These keys are used to display pxevious sequences of blood glucose tests or insulin injections.
The "YES" and "NO" keys are pressed in response to a prompt on the LED display requiring a yes or no answer.

3~ ~ ~t~ S

Referring to Fig. 2, an illustrative embodiment of the monitor system 10 is described~ In the exemplary arrangement illustrated, a reflectance photometer 130 is provided for obtaining blood glucose values. The analog output of the photometer is digi-tized by an analog to digital converter (ADC) 58 and fed into the system through a data selector 60.
The system also employs a timer 52 and a modem-coupled I/O port including a receiver 64 and an output driver 66. Timer 52 is controlled to give patient alarm signals, in a manner described subsequently and the receiver 64 and driver 66 provide an I/O port for inputting physician data and for coupling monitor data to a physician's operating system via, for example, a telephone communication channel.
Monitor 10 includes a microprocessor (MPU) 150 for providing necessary data storage, calculating and control functions. The system includes an input/output controller section 150a and a data bus 156 for chan-nelling data to and from the MPU. Data selector 60 anda shift register 50 are used for coupling the ADC 58, timer 52 and the modem I/O port to the MPU. The keyboard unit 11, display unit 12, a random access memory (R~M) 152 and a read only memory (ROM) 15~ are interfaced to the MP~ through the data bus 156. An audio output unit 13 is also connected to bus 156 and is operated to provide "beep" signals to the patient during certain operations, as described hereinafter.
The monitor may utilize, for example, a Sharp model PC 1500A microprocessor system which has been modified by the addition of the elements shown above I/O
controller 150a in Fig. 2 and more particularly illustrated in Fig. 3.

~3~35 g The reflectance photometer 130 operates to allow the patient to obtain accurate blood glucose readings simply and without physician assistance. The patient smears a blood sample (obtained, for example, by pricking a finger) on a conventional blood glucose test strip. After drying the strip for a predetermined time, the patient inserts the strip in the strip guide 14 (Fig. 1) and the system automatically reads the strip and enters a blood glucose value into the system in a manner described subsequently.
A schematic diagram of the hardware for obtaining blood glucose readings is shown in Fig. 3.
Analog data selector 60 is coupled to the analog-to-digital converter 58, which may be a 12-bit unit iden-tified by the "7109" model designation. Analog data selector 60 is coupled through inverting buffer 54 to the input pin 2 of timer 52. 8-bit shift register/latch 50 is coupled to timer 52 and through inverting buffer 54 to analog data selector 60 and A/D converter 58.
Additionally, the RS 232 receiver 64 is coupled to receive an input from a telephone modem (not shown) and to feed the modem signal into the system via data selec-tor 60. R5232 driver circuit 66 is coupled to transmit RS-232 compatible output signals to the telephone modem from the monitor system. Driver 66 is also coupled to buffer 5~ to receive RS 232 outputs from shift register 50. A reference voltage generator 62 is coupled to ana-log data selector 60 and to the optical circuit of the reflectance photometer to provide a precision voltage reference thereto.
The reflectance photometer 130 operates to pro-vide accurate blood glucose readings through the use of a light emitting diode and a phototransistor 72. The patient smears a blood sample (obtained, for example, by ~3~3~

pricking a finger) on a conventional blood glucose test strip and follows a sequence of computer-genera-ted prompts displayed on display 12. Ater drying the strip for a predetermined time, the patient inserts the strip in the strip guide 14 (Fig. 1) and the syste~ automati-cally reads the strip and enters a blood glucose value into the system in a manner described subsequently.
The analog data selector 60 is a type-4529 LSI
semiconductor chip. It controls the application of inputs to and the transmission of outputs ~rom the A/D
converter 58. Photometer ou-tput voltages produced by phototransistor 72, which reads the test strip, are coupled through amplifier 73 to input pin 14 of selector 60. Selection inputs applied to pins 6 and 7 from the channel 0 and channel 1 outputs of shift register 50 cause the signal on data selector pin 14 to be connected to output pin 10, whereupon the photometer signal is applied t~ input pin 35 of the A/D converter. The A/D
converter is a type 7109 chip that digiti~es the voltage at pin 35 under the control of the MPU 150. The latter provides a sequence of clock pulses at input C7 (Fig. 3, lower left) which is applied through buffer 54 to A/D
clocking input pin 22. The A/D converter issues a sta-tus pulse at its output pin 2 after a number of clocking inputs. The status signal is transmi-tted to the MPU via pin 9 of the data selector 60. The number of clocks which are required to generate the status output is representative of the level of the analog input. The MPU 150 therefore calculates a digital photometer reading by transmitting clocking inputs to the A/D con-verter and monitoring the A/D status output while counting the number of applied clocking inputs.
The 12-bit analog-to-digital converter provides exceedingly precise measurements of output voltages from 13~ S

the glucose reflectometer circuit. Most monitors used for reading blood glucose levels are ~-bit systems and their peripheral chips are al,so 8-bit devices. However, the system of the present invention uses the 12-bit analog-to-digital converter chip's internal clock to measure the time of discharge after a single sample is convertad. Since the rate of dischar~e is linear and constant, the system derives through software control a highly accurate reading using this technique. The MPU
stores the digitized blood glucose reading under control of ~irmware in a manner more fully described subsequently.
Timer 52 is used under control of the MPU 150 to provide timed alarms in the ~orm of "beeps" to signal lS the patient that various operations must be performed.
The I~PU enters data in parallel to inputs 9-12 o~ timer 52. This is done by feeding data through shlft register 50 and applying it from output pins 4-7 of the latter to the timer inputs. The data thus entered sets a time value into the timer and "Channel O" signal from shift register output 12 subsequently initiates operation of the timer. Upon timeout of the timed interval timer 52 sends a signal to the MPU I/O control terminal B7, whereupon MPU takes the appropriate action, such as pro-ducing a "beep" sound through audio unit 13 andtriggering a prescribed software routine to give the patient the necessary prompts, etc.
The monitor system can be used with a com-munications modem to communicate with a physician's base station over a telephone line. A rnodem coupled to the telephone line supplies inpùts to receiver 64, which is a type-1489 chip implementing the "RS 232" communication protocol. Received data is channeled to MPU liO via the data selector 60, which connects the signals applied to ~L3~

its input pin 5 to MPU input B2 via output pin 9. ~PU
generated data supplied on input Bl (Fig. 3, lower le~t) to shift register 50 is transmitted ~rom shift register output pin 13 and sent to the mode~l via buffer 54 and RS-232 output driver 66, whereupon the data is placed on the telephone line.
As shown in Fig. 4, a physician base computer 102 is coupled to a modem 104 and to a text and graphics printer 110. Physician's computer 102 implements an algorithm for evaluating glucose and patient data from the monitor system 10. The data is evaluated according to the prescribed algorithm, and the patient's insulin prescription may be adjusted in response to the eva-luation and transmitted to the monitor 10 via the modem link.
The monitor 10, operating independently of the modem link allo~s a patient 114 to use and evaluate glu-cose, insulin and behavioral data on a daily basis.
Accumulated patient data is communicated to the physi-cian's computer 102 through the modem link and computer102 evaluates the data to produce a patient report 112 using text and graphics printer 110. The report pre-sents a complete display of the analysis oE the data received from the patient 114 via the monitor 10. The physician 100 interprets the report results and depending on his analysis, may revise assessment parame-ters, dietary, and/or insulin prescriptions.
The physician may then reprogram the monitor system by changing the assessment parame-ters or die-tary, insulin, or other prescription stored within the moni-tor. This can be done by data inputs applied to the monitor directly at the physician base station or remo~
tely over the modem channel.

`S

In accordance with the embodiment sho~n~ the monitor system includes key switches (shown in Fig. 1) for the pa-tient to enter data indicating whether he is ma~ing a scheduled entry, an unscheduled entry, special functions or reviewing the data, and a number pad for a patient 114 to enter data. In exercising such a program option, when a patient 114 is making a scheduled entry, of which he would make up to eight scheduled entries per day, the patient depresses the scheduled entry key switch SE. Broadly, this option of the monitor system allows the patient to enter and record data according to physician prescribed assessment parameters. These may include the display of a prescrlbed basal insulin dose, recording insulin doses administered, base insulin dosage adjustment, supplementation of insulin doses to be prescribed, blood glucose, urine ketones or acetones, assessment of exercise and emotional stress, and assessment of body weight and dietary information. Eor an unscheduled entry, the patient 114 optionally records blood glucose and/or insulin taken during an unscheduled time period.
The use of the monitor system typically includes the operation of testing for a blood sugar level. The patient may perform the blood sugar test either as part of a Schedu1ed Entry or as part of an Unscheduled Entry.
To perform the blood sugar testing routine, the patient must have the monitor system 10, a lancet device, a bottle of "Dextrostix" strips (or similar type o~
reagent strips), a wash bottle with ~ater and blotting paper. Typically the patient will assemble the lancet device and then wash his hand in warm, soapy water. The patient then removes one Dextrostix strip from the bottle. The monitor system is turned on by pressing the ON key. Subsequently, either the SE or the UN key is depressed. After a sequence of preliminary prompts, the *trade mark ~4 ' ~3$~3S
-14~
blood sugar test is initiated when the monitor displays "PRICK ~INGER <E>." This signals the patient to prick the finger with the lancet device and obtain a drop of blood. After the drop of blood is obtained, the patient picks up the test strip with his free hand and presses the ENTER key.
The monitor system proceeds to prompt, "APPLY
BLQOD AT BEEP." In four seconds the monitor produces a "beep" from its audio unit 13, which is the patient's signal to apply the blood onto the pad of the test strip. The monitor system then counts down 60 second intervals.
After 60 seconds, the monitor again beeps and displays the prompt, "WASH STRIP." This is the signal to rinse the blood off the strip, using a thorough, even wash for about 2-3 seconds. The monitor then beeps and prompts the patient, "BLOT STRIP " The patient at this point will blot the test strip onto a paper towel twice. Another beep is generated b~ the monitor system and the prompt "INSERT STRIP <E>" is displayed. This is a signal for the patient to insert the strip into the glucose reflectometer strip guide 14~ When the strip is properly inserted, the patient presses the ENTER key switch.
The monitor system pauses for a few seconds, while it di3plays "READING BLOOD GLUCOSE." During this time, the monitor system is determining the blood glu-cose sugar value by reading the color of the test strip using reflectance photometer 130. Subsequently, the monitor displays "BLOOD SUGAR: Evalue] <E>.ll The moni~
tor automatically stores the blood sugar value into its memory 152, eliminating erroneous or deliberately misleading recordings common with pencil and paper methods. After the patient has seen the blood sugar ~3~3t5 value displayed, the patient is ready to proceed to the next assessment module, and presses the E~TER key switch. This completes the internal blood sugar test.
The reagent strips used with the monitor systems are capable of measuring blood sugar level because the pad on the strip contains chemicals which detect and react with glucose. When a drop of blood is placed onto the pad, the glucose in the blood starts to react with the chemicals in the pad. The pad begins to develop a blue color. A low blood sugar produces a light blue color, a high blood sugar produces a dark blue color.
When using the "Destrostix" type of reagent strip, the blood must remain on the pad for exactly 60 seconds for the pad to develop the correct color to indicate the level of blood sugar. If a person's eyes were very sensi-tive to color shades, the person could determine his blood sugar by comparing the color of the pad with a special color chart, such as the one on the side of the "Dextrostix" bottle. If the person examines this color chart, the person would realize that the sha-des "look a lot alike" and only six blood sugar levels are listed.
The monitor system 10 employs a special optical system, the glucose reflectance photometer 130, pre~
viously described in connection with Fig. 3, for distinguishing a large number of color shades. Each shade of blue or other color corresponds to a certain blood sugar level. The monitor 10 can be programmed so that other types of reagent strips can be used. In such a case an adjustment in the A/D converter control soft-ware would also be required to provide correct conver-sion values.
The results of the blood test are displayed as a number. This number indicates the amount of glucose per ~3~

unit of blood in milligrams per deciliter, abbreviated as "mg/dl."
When a patient works with a physician, the patient and physician usually have agreed upon certain times that the patient will routinely perform a blood test and/or take an insulin shot. The monitor lO is programmed to know when a patient is scheduled to per-form a blood test or to take an insulin shot. This information is entered into the computer memory 152 as prescribed by the physician. Usually the scheduled time is not an exact time, but is a time relative to a meal, such as before or after breakfast, before or after lunch, before or after dinner or at bedtime~ A
"Scheduled Entry" is an entry performed when the patient does a blood test or takes a shot of insulin at a prescribed and expected time, relative to the appropriate meal. There may be times however that the patient performs an extra blood test, or takes an extra shot of insulin. For example, the patient may desire to check to see if his blood sugar is low or perhaps an infection has caused the patient's sugar to rise, suggesting the need for an extra shot of insulin.
Whenever these situations occur, they give rise to an "Unscheduled Entry."
Each time the patient performs a scheduled entry, the monitor aslcs the patient about previous insu-lin reactions, exercise, emotional stress, illness, weight and dietary inta~e. Each of these factors may change the patient's blood sugar.
In recording insulin reactions, the monitor system prompts the patient to enter information about recent insulin reactions, by asking "LOW BLOO~ SUGAR
SYMPTOMS SINCE LAST ENTRY--Y/N?" If a patient has not had sy~ptoms of low blood sugar since the last scheduled - ~3~

entry and the patient does not feel he is having a reac-tion now, the patient enters NO to give a no answer. lf the patient has had symptoms of low blood su~ar since the last scheduled entry or if the patient feels these symptoms now, the patient enters YES to give a yes answer. The monitor system then asks the patient when he had those symptoms, by displaying, "LOW BLOOD SUG~R
SYMPTOMS NOW--Y/N?" In response to this prompt, the patient presses NO if the patient does not feel he is having symptoms of low blood sugar now and YES if one feels he is having symptoms of low blood sugar.
In recording exercise, the monitor prompts the patient for information about activity, by asking, "EXERCISE (1-5~?" The patient will then enter the measurement of exercise or activity since the last sche-duled pre-meal entry, using the following scale.
1 = substantially less exercise than usual for this time of day.
2 = somewhat less exercise than usual for this time of day.
3 - usual amount of and type of exercise for this time o~ day.
4 = some~lhat more exercise than usual for this time of dayA
5 - substantially more exercise than usual for this time of day.
Note that the patient is being asked how active he has been compared with his usual amount of activity for the period of time since the last scheduled entry.
For example, while the patient sleeps the patient does not exercise. The next morning, for a pre-breakfast entry, this would be entered as a "3", i the patient actually slept through the night. ~owever, if for some reason the patient were awake half the night pacing about the house, for the pre-brea~fast entry the patient would enter a "4" as a rating of the patient's night exercise.
Likewise, if the patient usually runs five miles every afternoon the patient would enter a "3" for the pre-dinner exercise entry on days that the patient runs five miles. However, if the patient were unable to run one afternoon because the patient had to work late, the patient might enter a "1" for his pre-dinner exercise entry.
In recording emotional stress, the monitor system prompts the patient to enter information about emotional stress by asking "EMOTION~L STRESS (1-5)?" In response, the patient enters the measurement of emo-tional stress the patient has felt since the last sche-duled entry, using the following scales:
= substantially less stress than usual for this time of day.
2 = somewhat less stress than usual for this time of day.
3 = usual amount and type of stress for this time of day.
4 = somewhat more stress than usual for this time of day.
5 = substantially more stress than usual for this time of day.
In recording illness, the monitor system prompts the patient to enter information about illness by asking "ARE YOU SICK--Y/N?" The patient presses ~0 if he has not felt sick since the last scheduled entry, ending the assessment of illness. If the patient presses YF.S, the monitor system displays, "HAVE A FEVER--Y/N?" The patient responds by pressing YES or NO.

~3~

If the physician desires the patient to keep track of body weight, the monitor prompts the patient each morning before breakfast with the question, "RECO~D
BODY WEIGHT--Y/N?" The patient will press either NO or 5 YES, depending upon whether the patient weighed himself that morning. If the patient responds YES the monitor prompts, "ENTER WEIGHT <E> . " The patient must then enter the weight value in pounds, followed by actuation of the ENTER key.
l0~he monitor is able to collect dietary infor-mation in three different ways. The physician will spe-cify which way the monitor should ask about food intake to reflect the way best suited for the individual patient based on his motivation and education in quan-tifying dietary intake. The first method uses a 1-5 scale to record dietary intake. If this method is cho-sen, the monitor system prompts, "FOOD INTAKE (1-5)?"
The patient will then enter the number which best describes his food intake since -the last scheduled 20 entry:
1 - none or almost no food for that meal or snack.
2 = somewhat less than usual (but a least 75%
of usual intake).
253 = usual amount and type of food for that meal or snack.
4 = somewhat more than usual (but less than 25%
more than usual).
5 = much more than usual.
30The second method uses calorie counts to record dietary intake. If this method is chosen, the monitor system displays the prompt, "DIET [Calories]: <E>."
The patient will then enter the number of calories the patient has eaten since the last scheduled entry.

~3~

The thir~ method calls for an input of food exchange data.-The monitor system is capable of reviewing pre-vious blood sugar values. This can be accomplished by the following procedure. First the patient turns the monitor on by pressing the ON key. Then the patient selects the review data option by pressing the RD key.
The monitor displays the prompt, "~EVIEW DATA." The display then tells the patient that the data will be presented with the most recent first. Then the display asks the patient whether he wants to review the data one test at a time, "l-EACH", or one day at a time "2-BY
DAY." In response, the patient presses "1" if he wishes to review each blood sugar test value and associated insulin administration record, one at a time. The patient presses "2" if he wishes to review t11e blood sugar values one day at a time, viewing premeal entries of blood sugar and insulin only~
If the patient presses "1", the most recent blood sugar and insulin levels are displayed along with the data concerning date, time, and types of insulin administered. For example the following information describes a breakfast schedule entry:
Dtl5 Brk B = 111 R12 N15 The date is the 15th of the month (Dt = date) and the recorded blood sugar was 111 mg/dl. The amount of R
type of insulin taken was 12 units and the amount of N
type insulin recorded was 15 units. Pressing the upward arrow key (~ will continue to present the data moving backwards in time. By pressing the downward arrow key (~), the data will be presented moving forward from the displayed time. When one has seen all the data stored in the monitor, the display will read "END OF DATA, AGAIN- Y/~?" The patient will press YES if the patient ~L3~?~

wants to continue viewing the information, and will press N0 if the patient does not. The patient may press the CANCEL key to interrupt the display whenever the patient no longer wants to look at the data. In response, the monitor system displays "CANCEL
ENTRY--Y/N?" The patient presses YES and the monitor turns itself off.
If the patient chooses to review data under the "by day" option, the monitor displays two lines to let the patient know how the information will be presented.
The first line indicates l'PREMEAL BLD SUGAR BY DAY" the second line will indicate l'FORMAT DAY BRK LUN DIN LtN."
With this option the monitor displays only the scheduled blood sugar tests performed before meals (PREMEAL) and at bedtime (LtN - latenight). Unscheduled blood tests and those performed after a meal (2 hours post prandial) will not be displayed.
The blood sugar values will be displayed in the following order: pre-breakfast blood sugar, pre-lunch blood sugar, pre-dinner blood sugar, then bedtime blood sugar. The data from the most recent day will be displayed first. For example, Dtl9 112 --- 143 95 This display tells the patient that on the 19th day of the month (Dt = date), his pre-breakfast blood sugar was 112 mg/dl. No blood sugar test is reported for the pre-lunch time, either because the patient did not do a test at the time or because the pre-lunch time is not a scheduled entry time for him. His pre-dinner blood sugar was 143 mg/dl, and his bedtime blood sugar was 95 mg/dl.
By pressing the upward arrow key to review the blood sugar values for the previous day, the data displayed on display screen 12 will move backward in ~3q;~

time. Again, when the patient has seen all the data stored in the monitor, the display will read "END OF
DATA, RGAIN--Y/N?" The patient presses YES i~ the patient wants to continue viewing the information ~nd NO
for not viewing the information. The patient may press the CANCEL key to interrupt the display whenever he no longer wants to look at the data. In response, the monitor displays "CANCEL ENTRY--Y/N?" When the patient presses YES the monitor turns itself off.
The monitor also implements several special functions. These special functions can be activa-ted by first turning the monitor on by pressing the ON key and then by pressing the X key. The monitor then prompts the patient to select the function desired by entering an appropriate number:
1 - DS Function to change the display speed.
2 - BEEP Function to change the monitor alarm.
3 - XMIT Function to transmi-t data to the diet care central computer over the tele-phone.
4 - TIME Function to change the current date/
time information in the monitor.
The change speed ~unction is activat0d by pressing the 1 key. The display indicates "THE DISPLAY
NOW FLASHES (pause). THIS F~ST -Y/N?" In the underlined blank, the system displays a number between 20 and 255, wherein 20 is the fastest speed and 255 is the slowest. In response to the patient depressing the NO button, the monitor system prompts the patient to enter the speed desired, by promp~ing "NEW SP~ED (20 -255): <E>." The patient presses the appropriate number keys, then presses the ENTER key.

~ll3~

The monitor then flashes the previously displayed two lines across the display at the new selected speed so that the patient can judge if the speed is too fast or too slow. These lines include:
THE DISP~AY NOW FLASHES (pause).
T31IS FAST - Y/N?
The process is repeated until an appropriate speed has been selected.
If the patient selects special function no. 2 "BEEP", a majority of monitor alarms can be turned on and off. The monitor beeps at certain times to make the patient aware of problems or to signal the patient to perform a procedure. The system produces beep sounds through the operation of audio unit 13, which is controlled by the MPU 150 and timer 52 (Figs. 2 and 3).
This may occur as part of a blood sugar test routine, or the alarm may be signaling the patient that it is time to undertake a scheduled entry.
However, there may be times when the patient does not want to have the monitor make any sounds, perhaps when there are others around and the beeps may be distracting. The "BEEP" special function allows the patient to turn off many of the beeps. There are some beeps that cannot be turned off, however. If the moni-tor alarm is turned off, the only beeps that will remainare those which are needed to time certain procedures such as applying or moving blood from a reagent strip during a blood sugar test. If the beeps are turned off, it is important that the patient watch the display screen carefully. The alarm system used to signal the patient to initiate a scheduled entry is enabled and set for various times by the patient's physician using co~-puter 150.

~L3~

The ~onitor system can additionally be used to transmit data by selecting special function no. 3 "XMIT." This function is used when it is time to con-nect the monitor to the telephone to transmit infor-mation to the central computer 150.
Typically, once a week a patient transmits(usually) in the evening the data that has been stored in memory 152. When a patient is ready to transmit data, the patient must assemble the following equipment:
- 10 the monitor, the modem, a.nd a telephone cord to connect the modem to the phone jack. The modem is plugged into a wall outlet for electrical power. The modular adapter is attached to the telephone wall box and left in place.
This allows the patient to use the modem without discon-necting the telephone, and at the same time, the adapter will not interfere with the normal function of the telephone. The use of MODEMS connected for data transmissions are well known in the art and their actual use as embodied herein is not further discussed.
In response to the patient pressing the 4 key to select the "TIME" special function, the patient can check and/or change date and time i.nformation. Upon entry into this module, for example, the following prompt is displayed:
TUES 1-1-86 14:53 - Y/N?
If the patient conEirms the current information is correct by pressi.ng Y this module is e~ited. If the patient responds by pressing the NO key, then the following prompts appear for entry:
Year? <E>
Month? <E>
Day? <E>
Hour (0-23~? <E~
Min? <E>

~3~

When completed, the newly entered date and time infor-~ation i3 confirmed by the patient as indica-ted above.
The various functions of the moni-tor system are controlled by computer programs stored in the system's me~ory in either RAM 152 or ROM 154. Programs which are relatively non-changing are stored in the ROM module ~nd are changed only by replacing the module in a system servicing environment. Programs stored in the RAM
module are readily changeable by reading new program data into the system via the modem I/O port. Programs are referred to herein as "firmware" wi-thout regard to the particular memory module in which they reside.
Fig. 5A depicts the hypoglycemic symptom assessment program module. Referring to Fig. SA, the patient specifies the time of day in step 202 by pressing YES or NO, on the monitor system keyboard 11 (Fig. 1) in response to the following sequence of firm-ware controlled prompts which appear on LED display 12:
3-AM TEST Y/N?
PRE-BREAKFAST Y/N?
POST-BREAKFAST Y/N?
PRE-LUNCH Y/N?
POST-LUNCH Y/N?
PRE-DINNER Y/N?
POST-DINNER Y/N?
LATF. NIGHT Y/N?
OTHER TEST Y/N?
In response to the relative recording time input, the program in the monitor system then proceeds to the determination of hypoglycemic symptoms.
As shown in Fig. 5A, the hypoglycemic value is set to an initial value of "0" (step 203). A deter-mination is then made in step 204 as to whether the -- ~3~

hypo~lycemic module has been pre-enabled by the physi-cian. If the hypoglycemic program module 204 is not enabled, the program will proceed to the next program module.
In assessing the hypoglycemic symptoms~ a deter-mination is made as to whether low blood sugar symptoms have been exhibited since the last execution of the program module. The LED display 12 prompts the patient with, "LOW BLOOD SUGAR SYMPTOMS SINCE LAST E~ITRY? - Y/N?"
10 (step 206)~ In response to a NO input from the patient, the program proceeds to the next assessment program module. In res3?onse to a YES, the program module sets the hypoglycemic value equal to "1" (step 207) and then displays the prompt "LOW BLOOD SUGAR SYMPTOMS NOW?" (s-tep 15 208). In response to the patient depressing NO, the program proceeds to the next assessment module. In response to a YES, the program module sets the hypogly-cemic value equal to "2" (step 210) and proceeds to the next assessment module.
Fig. 5B shows a blood glucose assessment program module. A determination is made in step 222 as to whether the blood glucose assessment module has been enabled by the physician. If 30, then the display 12 prompts the patient "USE CONTROLLED BLOOD SUGAR TEST
25 Y/N?" (step 224). If patient responds YES, then in step 226 the patient is prompted through a series of care~
fully timed steps to accurately determine the patient's blood glucose level using the system's local photoreflec-l:ometer system. If the patient responds NO, then the 30 monitor asks, "USE ANOTHER BLOOD SUGAR TEST Y/N?" (step 228). If the patient depresses NO, the program proceeds to the next assessment module. If the patient depresses YES the monitor prompts the patient to record the blood sugar value (step 230) derived from an external glucose 3~i assessment method. After the patient records a blood sugar value into the monitor the program proceeds to the next assessment module.
The controlled blood sugar test shown in step 226 is implemented as follows. The patient is initially prompted to prick a finger and subsequently to apply a blood smear to a standard chemically treated test strip at the end of a 4-second, beep-terminated countdown.
The program module then proceeds through a 60-second countdown and sounds another beep. After this beep, the patient is prompted to wash the strip followed by a beep, then to blot the strip followed by a beep, and finally to insert the strip into the reflectorneter strip guide 14. At this point, the program implements an A/D
lS conversion cycle to obtain the blood gLucose reading through operation of ,~hotometer 130 and A/D converter 58. The reading is displayed on display 12 and is stored in RAM 152 when the patient actuates the ENTER
key. After entry of the reading, the program exits the blood glucose assessment module and proceeds to the next assessment module.
Fig. 5C illustrates the exercise assessment module, emotional stress assessment module, and illness assessment module. Initially a determination is made as to whether these assessment modules are enabled by the physician, for the relative time period selected by the patient for data recording. If an assessment module is not enabled the program proceeds to the next assessment module.
First a determination is made as to whether the exercise assessment module is enabled (step 242). If enabled, the program module prompts the patient (step 244) to enter an exercise value between the range of 1-5 ~3~

by displaying "EXERCISE (1-5)?" In response to opera-tion of one of the keys 1-5, the program proceeds to t~e next assessment module.
A determination is then made as to whether the emotional stress module is enabled (step 246). If enabled, the monitor prompts the patient (step 24~) to enter an emotional stress value between the range of 1-5 by displaying "EMOTIONAL STRESS (1-5)?" In response to the patient's actuation of a key 1-5, the program pro-ceeds to the next assessment module.
The illness assessment module is initiated aftera determination is made as to whether the illness assessment module is enabled (step 250). The display 12 prompts the patient, "ARE YOU SI~K - Y/N?" (step 252).
If the patient responds that he is not sick by pressing ~O, the program module sets the illness variable to "0"
(step 256) and exits the module. If the patient enters a YES, the monitor displays the prompt "~AVE A FEVER
Y/N?" (step 254). Upon entering a NO, the program module sets the illness variable to "1" ~step 25~) and proceeds to the next assessment module. If a YES is entered in response to the prompt in step 254, the program module, sets the illness variable to "2" (step 259) and proceeds to the next assessment module~
Fig. 5D illustrates the dietary assessment module. Initially a determination i5 made (step 262) as to whether the dietary assessment module is enabled. If enabled, the program determines which form o~ dietary assessment is to be used. Three forms of assessment are possible: food intake, caloric intake, and food exchange. rFhe display 12 prompts the patient to enter only the physician-specified assessment information per-taining to their diet.

~3~35 --2g--If the food intake module is enabled (step 264), the display promp-ts the pa~ient, "FOOD INTAKE (1-5)?"
(step 266). After entering a food intake value of 1 to 5, the algorithm proceeds to the next assessment module.
Alternatively, if the caloric intake assessment is prescribed as determined in step 268, the algorithm prompts the patient, "DIET CALORIES: <E~" (step 270).
The patient then enters a caloric value and the algorithm proceeds to the next assessment module.
As a third alternative, the physician may require the patient to use the food e~change system of the American Dietetic Association to assess dietary intake. If this module is enabled (step 272), the patient is asked, "ATE EXPECTED FOOD Y/N?" (step 27'~).
If the patient responds with a NO, the program module proceeds in step 276 to prompt the patient to enter correct exchanges for each food exchange category (milk, vegetable, fruit, bread, meat and fat). Upon entering correct exchanges, or if a YES was entered in step 274, the program proceeds to display food value for last quarter (step 278). As illustratively shown, Food Value Last Quad 278 shows carbohydrates at 32 grams, fat at 12 grams, protein at 7 grams, and calories at 3~2. After displaying these values, the program proceeds to the next assessment module.
If, however, in response to the prompt in step 274, the patient responds by pressing RD (REVIEW DATA), then in step 275, the program will display the patient's prescribed food values. The patient should then be able to determine the appropriate answer to the question "ATE
EXPECTED FOOD Y/N?," after which the program returns to step 274 and reprompts the patient.
Fig. 5E is a flow chart illustration of the body weight recording program module. First, a determination ~3~

is made in step 282 as to whether the module is enabled.
If enabled, then in step 284, the program module deter-mines whether the relative recording time, entered by the patient in step 202 ~Fig. 5A) was PR~-BREAKFAST. If so, the display prompts the patient "RECORD BODY WEIGHT
Y/N?" (step ~86). If not, then the program exits the module.
Upon entering a NO in response to the prompt of step 286, the program module sets the patient's body weight to "0" (step 290). If the patient enters a YES, then the program module prompts the patient to enter body weight in step 288. After this entry in step 28a, or alternatively setting weight equal to zero in step 290, the program exits the body weight recording module and proceeds to the first step of Fig. 5F.
The flow chart of Fig. 5F illustrates the program steps for determining whether the patient's diet, exercise, and stress are within a normal range or whether the patient is ill. First, in step 300, the monitor displays the message "EVALUATING". This display continues while the following steps are executed. Also in step 300, the variable DESI, representing diet, exer-cise, stress, and illness, is initiali~ed to "0" indi~
cating that diet, exercise, and stress, are within normal limits, and the patient is not ill. In the steps that follow, significant changes in the patient's normal pattern of die-t or exercise, a substantial amount of emotional stress, or a reported illness will cause the DESI variable to be set to "1".
Step 302 determines whether the exercise value entered in step 244 (Fig. 5C) is equal to "1" or "5".
If the amount of exercise is either substantially less than usual (1) or substantially more -than usual (5) for this time of day, then in step 306, DESI is set to "1".

~3~

Otherwise, the program continues to step 304. Step 30 determines whether the emotional stress value entered previously in step 248 (Fig. 5C~ is equal to "5", indi-cating substantially more stress than usual for this time of day. If so, DESI is again set to "1"; other-wise, the program continues with DESI unchanged. Step 305 determines whether the illness variable in Fig. 5C
is greater than zero. If so, indica-ting the patient is now ill, then in step 306, DESI is again set to "1".
In step 308, before checking the patient's diet, -the program first determines whether the patient uses calories or food exchanges to record dietary intake. If the calorie assessment program module ls enabled in step 268 (Fig. 5D), then the patient uses calories to measure intake. If the food exchange assessment module is enabled in step 272, then the patient uses food exchanges. If neither is enabled, then it is assumed that the patient records dietary intake on a "1-5" scale as provided in the food intake assessment module in steps 264-266.
Thus, if the patient uses either calories or food exchange values, the number of calories is tested in step 312 to see if it is within 25~ of the prescribed amount. The number of calories comes from either the patient's entry in step 270, or as calculated in the food exchange assessment program module in step 278. If the food intake measured in calories is outside the 25 range in step 312, then in step 314 DESI is set to "1", else it remains unchanged.
If the patient records food intake on a "1-5"
scale, then in step 310, the food intake value entered previously is tested to see if it is equal to "1" or "5", indicating none or almost no food for that meal or snack (1) or much more than usual (5). If food intake is either "1" or "5", then in step 314 DESI is set to "1" and the program proceeds to step 320.
As shown in Fig. 5G, a determination is made in step 320 as to whether the supplemental insulin adjust-ment program module is enabled. This module may beenabled for a particular patient according to the prescription entered by the physician, or it may be disabled only for certain entry times during the day such as when the patient is not scheduled to take any - 10 insulin.
The supplemental insulin adjustment module shown in step 330 operates on pre-meal blood sugar values only. When a high blood sugar (hyperglycemia) results ~rom a recent substantial change in one of the manage-ment variables of diet, exercise, stress, or illness(DESI), then the program module will calculate a supple-mental dose of short acting (regular) insulin to correct the hyperglycemia. Step 330 is further described in reference to the flow chart diagrams of Figs. 6A-6C
which illustrate the program steps for determining whether a supplement is needed and for calculating a supplemental dosage.
Step 340 determines whether the base insulin adjustment program module is enabled for this patien-t at this time. Base insulin refers to the insulin that is scheduled to be taken at a pre-meal entry time. A
single "target" insulin is selected ~or adjustment according to the pre-meal entry time. The target insu-lin is identified as the one most affecting the current blood sugar. The base insulin adjustment program module of step 340 will adjust the target insulin dosage based upon consistent blood sugar patterns. Figs. 7A-7H con~
tain flow chart diagrams which further illustrate the program steps embodied in step 340 ~or adjusting the base insulin.

~3~

Finally, in step 360, the program determines whether the insulin recording/administratiOn program module i9 enabled. This module may be disabled if the patient is not scheduled to take any insulin at this entry time. If it is enabled, then the insulin recor-ding/administration module shown in step 370 calculates the total insulin dosage and provides prompts to the patient on the monitor display. The program module depicted in step 370 i3 further illustrated in the flow chart diagrams of Figs. 8A-8F to be described subsequently.
Figs. 6A-6C taken together are a functional flow chart diagram of the supplemental insulin adjustment program module shown in step 330 (Fig. 5G). When high blood sugar results from a substantial change in the patient's diet, exercise, stress, or illness (DESI), the program module will suggest a supplemental dose o-E short acting regular insulin. The suggested dose will eit'ner be one unit of short acting insulin increased by one unit for each 50 mg/dl increment in the blood sugar over a set limit or a percentage o~ the current R base insu-lin. The limi-t at which a supplement will be suggested is normally set at a blood sugar value of 200 mg/dl, but it may be changed according to an individual patient's prescription.
If the patient has not entered enough infor mation about insulin, blood suyar, or other control fac-tors, or if the patient has taken an unusual or non-prescribed dose of insulin which could effect the current blood sugar, the program module will not attempt to calculate a supplement. Instead, a message will be provided on the monitor display to let the patient know why a supplement was not suggested. Also, the supple-mental insulin adjustment module will prevent an overlap ~3~

in insulin activity due to supplemental insulin doses.
For example, a recent increase in base insulin will can-cel a supplement at the next meal.
In reference to Fig. 6A, the irst step in the supplemental insulin adjust~ent module, step 400, deter-mines whether the current blood sugar (BS) exceeds the ~inimum level for which a supplement is given. The minimum is generally set at 200 mg/dl but may vary for individual patients. If the current blood sugar is less than the minimum for supplementation, then the program module is exited via the N branch of step 400.
The steps that follow, namely steps 402-436, test for certain conditions before a supplement is suggested. If any of these conditions are not met, then a message is provided to the patient as to why a supple-ment is not recommended and execution of the supplemen-tal insulin adjustment module is terminated In step 402, the program module checks to see if this is the first day the patient has used the monitor.
No insulin adjus-tments are allowed until the patient has been using the monitor for one full day because there is not enough information to prescribe a supple~ent. I~
this is the first day of monitor use, the program module displays the message "NO INSULIN SUPPLEMENTATION M~DE ON
E'IRST DAY" (step 404) and exi-ts. Otherwise it continues to step 406.
Step 406 determines whether a supplement is prescribed for the patient for this particular entry time. If not, then the message "SUPP NOT GIVEN BECAUSE
SUPP NOT RX'D FOR D~NNER" (step 408), for example, is displayed with the current entry time.
Step 410 checks the last two quadrants (e.g., if the current entry time is "DINNER", it will check the previous "LUNC~" and "BREAKFAST" entries) to see whether 9.~
~35-the patient has recorded a valid hypoylycemic condition.
The "valid hypo" flag is set whenever the patient has reported hypoglycemia symptoms tsee steps 204-210 in Fig. 5A) with concurrent low blood sugar below a prede-termined limit. This flag is also set if hypoglycemiasymptoms alone were recorded during sleep. Symptoms sufficient to cause waking are in a sense "self-validating." Step 410 is necessary because when the blood sugar level drops too low, it may rebound to a level above normal. In other words, the low blood sugar may be caused by too much insulin, so it is unwise to give more insulin until the blood sugar stabilizes again. Thus, if step 410 detects a previous valid hypo, then the message "SUPP NOT GIVEN BECAUSE PREV. LOW BLOOD
5UGAR ~AY BE REBOUND" is displayed and the program module exits.
Step 414 (Fig. 6B) checks the patient's previous data entry for the most recent scheduled dose of insulin The supplemental insulin adjustment program module will suggest an insulin supplement only if the insulin dose affecting the current blood sugar has been entered. If not, the program will display the message "SUPP NOT
GIVEN BECAUSE MISSING INSULIN DATA" ~step 416) and then exit.
In step 418, the program module tests the amount of insulin ta~en at the last pre-meal entry time to determine whether i~ was within one unit of that prescribed. If the patient took more NPH, semi-lente, or regular insulin than was scheduled, the effect of that extra insulin could overlap with a supplement given now. Therefore, the supplement is cancelled and in step 420, the message "SUPP NOT GIVEN ~ECAUSE EXTRA R INSULIN
TAKEN" is displayed, for example, indicating the type of insulin. Also, if the patient too~ an unscheduled (UNS) .

:~3~

dose of regular or NPH insulin during the past six to twelve hours, then the effect of that extra insulin may overlap with a supplement at this entry time. Step 422 checks for unscheduled insulin, and if -found, the message "SUPP NOT GIVEN BECAUSE UNS INSULIN TAKEN" (step 424) is displayed.
Step 426 determines whether the regular base insulin for this entry was recently increased or is going to be increased or decreased. An increase in base insulin cancels a supplement at this entry time for three days while the increase is being tested. A sche-duled decrease in insulin cancels a supplement at this entry time only. Thus, if either of the conditions of step 426 are met, then in step 428, the program displays the message "SUPP NOT GIVEN BECAUSE BASE INSULIN IS
INCR'd", for example, indicating whether the base insu-lin was increased (INCR'd) or decreased (DECR'd).
Similarly, step 430 determines whether the NPH insulin most recently taken was increased or decreased. If so, the message "SUPP NOT GIVEN BECAUSE PREV. N WAS INCR'd"
(step 432) is displayed with either an increase (INCR'd~
or decrease (DECR'd) indicated.
Step 434 (Fiy. 5C) tests the DESI variable which was set in steps 300-314 of Fig. 5F. Insulin supple-ments are prescribed only during illness or substantialchanges in diet, exercise, or stress. Thus, if DESI =
(normal) then a supplement will not be given and the message "SUPP NOT GIVEN BECAUSE NOT SICK OR DESI NORMAL"
(step 436) is displayed. If DESI = 1 (abnormal), however, then in step 438, the monitor will display the message "INS SUPP NEEDED".
Steps 440-448 calculate the supplemental dosage according to either of two methods. Step 440 will first determine which method is prescribed by the physician ~3~lq~

for this particular patient. The first method (A), steps 442-446,-calculates the supplement based on 50 mg/dl increments in the cur.ent blood sugar over the minimum blood sugar for a supplement. In step 442, a temporary variable TMP-BS is set equal to this minimum, generally 200 mg/dl. The supplemental value (SUPP) is set to zero. Step 446 tests the current blood sugar (BS) against the variable TMP-BS and TMP-BS against the minimum blood sugar for a supplement plus 200. If either the current blood sugar (BS) is less than TMP-BS
or TMP-BS is greater than 200 plus the minimum blood sugar, then the calculation of the supplement is complete. If not, then in step 446, TMP-BS is increased by 50 and SUPP is increased by 1. Thus, for each incre-ment of 50 mg/dl in the current blood sugar over theminimu~, SUPP will be increased by one unit.
The alternate method o~ calculating the supple-ment (B) shown in step 448 uses a prescribed percentage of the current R insulin base. The current R base i3 defined as the most recently scheduled base dose of R-type insulin. SUPP is determined b~ taking the prescribed percentage of the current ~ base and rounding it off to the nearest unit, but in no event less than one unit.
Figs. 7A-7H taken together are a ~unctional 1OW
chart diagram of the base insulin adjustment program module shown in step 340 (Fig. SG). The base insulin adjustment module operates on a single "target" insulin selected for adjustment according to the pre-meal entry time. For the most part, this single identified dose of insulin is considered, with relevant blood sugar and behavioral data, during adjustment.
When undesirable patterns of blood sugar values occur consistently and without apparent cause from .

~3~ 35 -3~-substantial change in die~, exercise, emotional stress, or illness, the insulin dosage should be adjusted.
Generally, a distinct pattern of consistently high or low blood sugar must occur for three days be~ore any adjustment is attempted. I~ the patient has not entered enough information about insulin taken, blood sugar, or other control factors, or if the patient has taken an unusual or nonprescribed dose of insulin recently, the program module will not attempt to calculate an increase or a decrease in the identified base insulin. Instead, a message will be provided on the ~onitor display to let the patient know why the base insulin is unchanged.
In general, the base insulin adjustment module will suggest a decrease in insulin if the patient has a blood sugar value below a certain predeterlnined limit (usually 60 mg/dl) at approximately the same relative time for two days in a row, or i~ the patient has one occurrence of a blood sugar value less than 46 mg/dl.
Decreases in base insulin are bas~d on all low blood sugar values, even those which do not occur before meals. The target insulin will not be decreased if the low blood sugar was apparently caused by a substantial change in diet, exercise, emotional stress, or illness ~DESI). Only one decrease in base insulin for any entry time will be suggested during a ten-hour period.
If a given pre~meal blood sugar value is con-sistently greater than a certain predetermined limit (usually 140 ~/dl~ for three consecutive days at the same entry time without an apparent cause from a substantial change in diet, exercise, stress or illness, the program module will suggest an increase in the iden-tified base insulin. Only one base insulin dosage increase will be suggested during a three-day period to avoid a possible overlap in insulin activity and to q~

allow time to assess the effects of one change before a second change is made. Also, before the program will try to correct an elevated fasting (i.e., pre-breakfast) blood sugar pattern, the patient will be prompted to perform a 3:00 a.m. blood sugar test. The relevant base insulin dose will then be increased or decreased depending on the results of the 3:00 a.m. blood sugar.
In reference to Fig. 7A, step 500 first deter-mines whether any adjustment in the target base insulin is required. One of three possible conditions must be met: either (1~ the current blood sugar is below a prescribed lower limit; (2) the current blood sugar is above a prescribed upper limit; or (3) the patient has recorded a valid hypoglycemia since this entry time on -the previous day. A "valid hypo" is generally defined as both reported hypoglycemia symptoms (see steps 204-210 in Fig. 5A) with concurrent low blood sugar below a predetermined limit but, as noted previously, the "valid hypo" condition may also be set if hypoglyce-mia symptoms alone were recorded during the night. If none of the conditions are met, then in step 502, the message "BLOOD SUGAR IN TARGET RANGE" is displayed and no adjustment to the base insulin is required.
The steps that immediately follow, namely steps 504-522, test for certain conditions before an increase or decrease to the target base insulin is suggested. If any of these conditions are not met, then a message is provided to the patient as to why an increase or decrease is not indicated.
In step 504, the program module checks to see iE
this is the first day the patient has used the monitor.
No insulin adjustments are allowed until the patient has been using the monitor for one full day because there is not enough information to make adjustments. If this is ~3~ 35 the first day of monitored use, the program module displays the message "BASE INS UNCHANGED DUE T0 MISSI~G
INSULIN DATA" (step 508) and then exits.
Step 506 checks the patient's previous data entry for the target base insuLin, which is normally the most recently scheduled dose of insulin. The base insulin adjustment program module will adjust the base insulin only if the insulin dose affecting the current blood sugar has been entered. If not the program will display the same message in step 508 and then exit.
In step 510, the program module tests the amount of insulin taken at the last pre-meal entry time to determine whether it was within one unit of that prescribed. If the patient took more or less insulin li than was scheduled, the effect of that altered insulin dose may interfere with assessment of the current sche-duled do.se. In step 512, the message "BASE INSULIN
UNCHANGED DUE T0 N0~-RX'D INSULIN TAKEN" is displayed if the pa~ient took non-prescribed insulin. If the patient took an unscheduled (UNS) dose of regular, semi-lente, NPH, or lente insulin during the last 5iX to twelve hours, then the effect of that extra insulin may also interfere with assessment of the prescribed insulin.
Thus, step 514 checks for unscheduled insulin in the last six to twelve hours, and if found, the message "BASE INSULIN UNCHANGED DUE T0 UNS INSULIN TAKEN" (step 424) is displayed.
Step 518 (Fig. 7B) tests the DESI variable whi~
is set in steps 300-314 of Fig 5F. It is impossible to determine if the dose of insulln is correct if, at the same time, there are substantial changes in the patient's diet, exercise, stress, and illness.
Therefore, no changes in base insulin are suggested unless DESI = 0 (normal) for two days. In the step 520, the message "BASE INSULIN UNCHANGED DUE TO CHANGE IN
DIET/EX/ST/ILL'' is given on the day that a substantial change in diet/exercise/streSS/illneSs is noted, then on the following day "BASE INSULIN UNCHANGED DUE TO CHANGE
IN DIET/EX/ST/ILL YESTERDAY" is displayed.
Step 522 checks for non-prescribed or missing insulin in the same manner as steps 510 and 514, only this time, the program looks at data at this entry time for the last two days. No decreases in the base insulin are recommended until a two-day pattern is established with a three-day pattern required for an insulin increase. If the data is not consistent for two days at this same time then the message "BA5E INSULIN UNCHANGED
DUE TO NON-RX'D OR MISSING INSULIN YESTERDAY" (step 524) is displayed.
If the program makes it this far without exiting, then in step 526, it is determined whether an increase or a decrease in the identified base insulin is generally indicated. If the current blood sugar is low, or the patient has reported a valid hypo, then the program continues, indicating a possible decrease. If neither condition is met, and thus the current blood sugar is high, then the program jumps to step 570 of Fig. 7E to further determine if an increase in the base insulin i3 needed.
If the current entry time i9 breakfas~ in step 528, then step 530 makes an additiona] check to see i~
the fasting (pre-bxeakfast) blood sugar has been high at this time for the last three days. In order to correct an elevated fasting blood sugar pattern, the base insulin adjustment program module executes a different set of steps shown in Figs. 7G-7H before calculating an increase or decrease. Thus, the Y branch of step 530 ~3~ l3~

will result in a jump to step ~00 lf the fasting blood sugar has been high for three days.
Continuing to step 532, this step begins a sequence of steps for determining whether the identified base insulin should be decreased. If a supplement was prescribed and taken in the previous quadrant (e.g., if the current entry time is "DINNE~", the previous quadrant is "LUNCH") then the base insulin will not be decreased. It is assumed that if the current blood sugar is low and a supplement was prescribed and taken, the supplement was the cause of the low blood sugar.
Thus, in step 532, if a supplement was taken, the program module will exi-t without changing the base insu-lin.
Usually, the base insulin adjustment program module will suggest a decrease in insulin only if the blood sugar is low at the same time for two days in a row. On a single occurrence of a blood sugar value less than 46 mg/dl, however, the program will recommend an immediate decrease. In step 534 (Fig. 7C) if the current blood sugar is less than ~6 mg/dl or a previous hypo had a concurrent blood sugar less than ~6, the program will skip steps 536-546 and go directly to step 550 (Fig. 5D) to calculate the decrease.
If in step 536, the base insulin was decreased at this same entry time on the previous day, then the base insulin will remain unchanged. In step 538, the base insulin adjustment program module also requires that the patient have either a low blood sugar or reported symptoms of hypoglycemia at this entry time on the day before in order ~o decrease the base insulin.
If neither condition is met, then the message "BASE
INSULIN U~CHANGED ~UST HAVE 2 LO BS I~ A ROW" (step 544) is displayed and the program exits.

~3~3~

As just described, either a low blood sugar or hypoglycemia symptoms alone on the previous dayl with current low blood sugar or hypo symptom5, are generally sufficient to decrease the identified base insulin. If, however, the current entry time is breakfast, today's hypoglycemia symptoms must be validated by concurrent low blood sugar. Thus, if the current entry time is breakfast and the current blood sugar is not low in step 540, the hypo condi-tion reported previously on this same day, either at ,he 3 a.m. test or at unscheduled (UNS) -time, must be validated. Step 5~2 validates the pre-vious hypo by checking the blood sugar at the same entry time. If the "hypo" is not valid and there is no con-current low blood sugar with the earlier recorded "hypo", the same message of step 57~ is displayed and the program exi-ts.
Step 546 determines whether there is sufficient base insulin prescribed from which to make a decrease.
If the current insulin is greater than zero, and an increase is not currently being tested, then the program module will continue to calculate a decrease.
Otherwise, the program will exit.
Step 550 (Fig. 7D) checks to see if any base insulin was decreased in the last 6-10 hours. In general, only like types of insulin separated by at least two quadrants (e.g., break~ast and dinner R type) or insulins separated by more than two quadrants (e.g., dinner R and the ~ollowing lunch N) may be decreased consecutively. If a recent decrease i5 found in step 550, then the message "CANNOT DECR DINNER N I~SULIN ONLY
1 DECR EVERY 6-10 HRS" (step 552), for example, is displayed, indicating the current entry time "DINNER", "LUNCH", etc., and the type of insulin, "R", "N", "S", or "~

~IL3~ a3~i Step ~44 indicates to the patient that all of the previous conditions for a decrease in base insulin have been met by displaying, for example, "NEXT DINNER N
WILL DECR". Steps 556-564 then calculate the actual 5 decrease in dosage. First, step 556 determines whether an increase in base insulin was previously prescribed in this quadrant. If so, then the base insulin will decrease by half the recent increase. Thus, in step 560, ~ INS, the change in the base insulin, is set equal to the pre~ious increase divided by two. If there was not an increase in the insulin identified affecting this quadrant's blood sugar pattern, then in step 558, ~ INS
is equal to 5% of the current base insulin rounded off to the nearest unit.
Finally, step 562 checks to see if this decrease is following a rebound pattern. A rebound is said to occur when the low blood sugar which prompted this decrease in base insulin is followed by an occurrence of high blood sugar. If so, the program module sets a "REBOUND" flag for the next three days to prevent any increases in the base insulin during this time. This flag is checked in step 582 tFig. 7E) before an increase is suggested.
Returning to step 526 (Fig. 7B), if the bloocl sugar value is high, then an increase is generally indi-cated and the program will jump to step 570. Steps 570-590 (Fi~s. 7E-F) make up the "increase" portion of the base adjustment program module.
First, in step 570, if the current entry time is breakfast, then the program module executes a different set of steps shown in Fig. 7G-7H for evaluating a high fasting blood sugar pattern~ Thus, the Y branch of step 570 will result in a jump to step 600.

~3~ S

Continuing if the current ti~e is not brea]cfast, in step 572, the program determines whether the blood sugar has been high at this entry time for the last three days. An increase in base insulin will be recom-mended only if the given pre-meal blood sugar value is consistently higher than the upper limit for three con-secutive days. If not, then the program module exi-ts without changing the base insulin.
Step 574 tests the DESI variable in the same ~anner as step 518, only this time, the program looks at data for the last three days. An increase in the base insulin is not recommended unless DESI = 0 (Normal) for three days. In step 575, the message "BASE INSULIN
UNCHANGED DUE TO CHANGE IN DIET/EX/ST/ILL TWO DAYS AGO"
is displayed if a substantial change is found two days previous.
Si~ilarly, step 576 checks for non-prescribed or missing insulin data over a three-day period. A three-day pattern is required before an insulin increase is recommended. If there is missing or non-prescribed insulin two days before this entry time, then the message "BASE I~SULIN UNCHANGED DUE TO NON-RX'd OR
MISSING INSULIN TWO DAYS AGO" ~step 577) is displayed.
Furthermore, only one increase in base insulin dosage will be suggested during a -three-day period to avoid a possible overlap in insulin activity and to allow time to assess the effects of one change before a second change is made. Thus, in step 578, if it is less than three days since the last increase, the message "MUST ~AVE 3 DAYS BETWEEN INSULIN INCR'S" (step 580) is displayed.
Step 582 tests to see if the REBOUND flag has been set by step 562 ~Fig. 7D). A rebound pattern detected by step 562 will disable any increases for the s -~6-next three days by setting this flag. If the REBOU~D
flag is set, then in step 582, the program exits wi-thout an increase.
In step 584, the monitor will display, for example, the message "NEXT DINNER N WILL INCP~" indi-cating the entry time "DINNER", "L~NCH", etc., and the type of insulin, either "N" or "R". Steps 5~6-590 then calculate the actual increase in the base insulin, ~INS.
Step 5~6 sets a temporary variable TMP-BS to the upper limit of the blood sugar value at which an in-crease is recommended, usually 140 mg/dl. A pointer variable P is set to zero. Step 588 tests the current blood sugar (BS) against the variable TMP-3S and TMP-BS
against the upper limit for any increase plus 250. If either BS is less than TMP-BS or TMP-BS is greater than 250 plus the high limit, then the calculation is com-pleted in step 5gO. If not, then in step 592, TMP-BS is increased by 50 and P is increased by 1. Thus, for each increment of 50 mg/dl in the current blood sugar over the upper limit, P will be increased by 1~ P is then used to identify one o-f several prescribed percentages dependent on the range of the current blood sugar.
INS is determined in step 590 by taking the ~re-scribed percentage o~ the current base and rounding it off to the nearest unit.
In order to correct an elevated fasting bLood sugar pattern, tl~e program module will execu~e the steps shown in Figs. 7G-7H before calculating an increase or decrease. The patient will be prompted to perform a 3:00 a.m. blood test and the base insulin dose will be increased or decreased dependent on the results of the 3:00 a.m. test. In step 600, the program module will determine whether the pre-break~ast blood sugar has been ~3~

high for the past three days. A change in insulin will be recommended-at breakfast only if the fasting blood sugar value is consistently higher than the predeter-mined limit for three consecutive ~ays. If not, then the program exits without changing the base insulin.
In step 60~, DESI is tested for an expanded three-day period as in step 574 (Fig. 7E). ~he appro-priate message is displayed in step 603 if DESI = 0 (abnormal) during this period. Similarly, step 576 checks for missing or non-prescribed insulin and a message is displayed in step 577.
Step 606 determines whether there has been at least two days since any prior fasting decrease in base insulin. This is to allow time to assess the effects of one change before a second change is made. In step 608, the program mGdule checks to see if the patient made a 3:00 a.m. entry today. A 3:00 a.m. measure is always required before a fasting insulin can be adjusted. If not, the patient is prompted to perform a 3:00 a.m.
blood sugar test the following day in step 610. If the patient has done a 3:00 a.m. test, then step 612 will display the result.
Step 614 tests the 3:00 a.m. blood s~gar value to see if it is greater than 99 mg/dl. Generally, iE
hypoglycemia symptoms are sufficient to wake the patient, then the symptoms are probably indicative of a low blood sugar. If any objective measure of the blood sugar at the same time contradicts this, however, i.e., blood sugar greater than 99, then the hypoglycemia value will be invalidated and reset to zero. This is because patient-reported symptoms of hypoglycemia are often un reliable and may actually be only a result of a drop from a high blood sugar level to a normal level. There-~3~J~

-~8-fore, if there is no concurrent low blood sugar, the hypo is invalidated in step 616.
In step 618, if it is less than three days since the last increase, the message "MUST EIAVE 3 DAYS BETWEEN
INSULIN INCRS" (step 620) is displayed. This is because only one increase in base dosage is allowed during a three-day period to avoid a possible overlap in insulin activity and to allow time to assess the effects of one change before another is made. Finally, in step 622, a decision is made based on the 3:00 a.m. blood sugar test as to whether an increase or a decrease in base insulin is indicated. If the 3:00 a.m. blood sugar is less than 100, then the program module jumps back to step 550 (Fig. 7D) and continues to calculate a base insulin decrease. If the 3:00 a.m. blood sugar is greater than or equal to 100, then the program returns to step 582 (Fig. 7E) and the steps that follow to calculate an increase in base insulin.
Figs. 8A-8F taken together, are a functional flow chart diagram of the insulin recording/administra-tion program module shown in step 360 (E'ig. 5F). I'he insulin recording/administration module calculates the total insulin dosage for this entry and provides prompts to the patient on the monitor display. Fig. 8A illus-trates the main functions of the recording/administra-tion program module. Figs. 8B-8D illustrate a subfunction of the program module called by the mair routine in Fig. 8A for computing the insulin dosages.
Fig. 8E-8F illustrate another subfunction called by both the main routine and the computation subroutine for checking the patient's data entry of insulin taken.

~3~

First, in s-tep 700, the insulin r~cording/admin-istration program module determines whether this is an unscheduled tuNs) entry. If it is unscheduled, then the insulin to be taken is merely recorded. Step 701 asks the patient "TAKE INSULIN NOW - Y/N?" If YES, then in step 702, the patient is prompted for each of two types of insulin used by the patient, for example, "R INSULIN
<E>" and "N INSULIN <E>." The patient will then enter the actual dose of each insulin taken and press the ENTER key. The program module will record and then check the patientls entry for miskeys only by executing the steps illustrated in Fig. 8E-8F. After this, the program module will exit and the sequence for this entry time is complete.
If this is not an unscheduled entry, then step 704 determines whether the patient needs to take any insulin now during this scheduled (SCH) entry. Step 704 will check to see if there is any R base insulin to be taken (Rb greater than zero), any ~ base insulin (Nb greater than zero), a supplement (SUPP greater than zero), a change in R base insulin ( ~ R not equal to zero) or a change in the N base insulin ( ~ N not equal to zero). If none of these is present, then the patient is not to take any insulin and the program exits.
Otherwise, the program continues to step 706.
Step 706 displays the message "INS~LI~ TO BE
TAKEN" on the monitor display. Step 706 then calcul a preliminary total of each type of insulin to be taken for use in steps 708 and 712. The total R type insulin to be taken is equal to the R base plus any change in the R base (increase or decrease) plus any supplement.
The total N type insulin to be taken is the N base insu-lin plus any change in the base. Step 708 determines whether the total R type insulin is greater than zero ~3~

and thus there is R type insulin to be taken at this time. If R is- positive, then in step 710, the steps shown in Figs. 8B-8D are executed for the R type insulin to calculate the total R insulin and provide prompts to the patient. Similarly, if N is positive in step 712, the same steps in Figs. 8B-8D are executed for the N
type insulin in step 714. After these steps, the program module will exit and the sequence for this entry time is complete.
Figs. 8B-8D taken together illustrate the sub~
function of computing the insulin doses executed in steps 710 and 714 of Fig. 8A. The steps shown in Figs.
8E~-8D are executed for both R and N types of insulin.
Step 720 determines whether only a supplement is to be given. If both the base insulin and the change in insulin are zero, then there must be a supplement. This will be the case only for R type insulin, however, because N type supplements are not considered possible.
Thus, in step 722, the insulin dose will be set equal to the supplement only and the monitor display will read "R
SUPPLEMENT 2 <E>", for example. After the patient enters the actual dose taken, the program module will record and then check the entry by executing the steps shown in Figs. 8E-8F.
If in step 724, the supplement is greater than zero, then the insulin to be taken is the base insulin plus the supplement. Again, this is only possible for R
type insulin and there will never he both an increase and a supplement prescribed at the same time. The patient is prompted, for e~ample, "R W/SUPP 5+1=6 <E>"
as shown in 726. lthe patient's entry is recorded and checked by the steps in Figs. 8E-8F.
If in step 728, the change in insulin is greater than zero, then the patient is obviously scheduled for ~3~

an increase in base insulin. Steps 730-734 are "house-keeping" steps to allow the patient to test an increase in base insulin over three days before the base insulin is permanently changed. In step 730, the variable DAYS
measuring the number of days since the increase was first scheduled is incremented by 1. If in step 732, DAYS is equal to 4, then the patient is beyond the three days since the original increase and this mu~t be a new change in the base insulin. As described previously, only one increase in base insulin is made in a three-day period to avoid possible overlap in insulin activity and allow time to assess its effects before a second change is made. If DAYS is equal to 4, then it is reset to zero in step 734. The DAYS variable is used subsequent-ly in step 752 to decide whether to make the increase tobase insulin permanent on the third day of testing.
In step 736, if the change in insulin is zero, meaning that there is no increase or decrease in the base insulin, then in step 738 the insulin to be taken is equal to the base. The patient is prompted "R
INSULIN 5 <E>", for example, and the patient's entry is recorded and then checked by the steps in Figs. 8E-8F.
Following step 738, the insulin computation subfunct;~
is complete and the program module sequence of execut~
will return to the main routine o Fiy. 8A.
In step 740 (Fic;. 8C), since the chanye in insu-lin is not zero (step 736), the lnsulin to be taken mus~
be equal to the base plus the change -- either an in c~ease or a decrease. If, in step 742, the total insu-lin is less than zero, then step 744 will set the amountof insulin to be taken to zero. The patient can obvi-ously never take a negative dose and this prevents the program from giving the patient a prompt with a negative value.

~3~

Step 746 determines whether an increase or a de-crease in the base insulin is scheduled. If the change in insulin is negative, then step 750 Eor giving and re-cording a decrease is executed. Otherwise, if the change in insulin is positive, then an increase is given in step 748 and those steps that follow.
In step 750, the message "R W/D~CR 5-1=4 <E>", for example, is displayed. The patient's entry is re-corded and then checked as in previous steps. The change to the base insulin is then made effective by setting it equal to the current base plus the change.
Since the change is in fact negative, i.e., ~ INS is less than zero, the base insulin will be decreased. The change in insulin is then reset to zero.
In step 748, a message such as "R ~ CR 5~1=6 <E~" is displayed indicating an increase in base insu-lin. The patient's entry of insulin actually taken is recorded and then checked. An increase to the base, however, is not made immediately. The patient will be instructed that he is taking an increase, but the base insulin will not be permanently changed until the end of a three-day testing period. Thus, i-f DAYS is not equal to "3" in step 752, the insulin computation sub-function is complete and the program will return to the ~ain routine of Fig. 8A. If this is the third day, however, the additional steps 754-764 will be executed before returning.
Step 754 cal~ulates a three-day average -for the insulin actually taken at this time. In step 756 (Fig.
8D), the three-day average is compared to the insulin that was to be taken at this entry time including the increase. If the patient has taken less insulin than was suggested for the last three days, then in step 758, the message, for exa~ple, "3 DAY AVE R DOSE = 5" is ~L.3~

~ 53-displayed, to inform the patient that he has taken less than the recommended increase during the last three days. In step 760, the patient will be asked whether he wants to make his base insulin equal to the three-day average rather than the greater recommended amount by displaying, for example, the message "MAICE R = 5 NOT ~
Y/N?". If the patient responds YES then the base insu-lin is set to the three-day average. The program has, in effect, "learned" a lesser dose o~ insulin based on the patient's responses. If the patient is being too conservative in not accepting the recommended increase, however, the base adjustment program module will subse-quently recommend another increase to the base dose.
If the patient rejects the three-day average in step 760, or the three-day average is the same as the current insulin because the patient took the recommended amount in step 756, then step 762 will be executed. In step 762, the change to the base insulin is ~ade by setting it e~ual to the current b~se plus the change.
Since the change is positive, i.e., ~ INS is greater than zero, the base insulin will be permanently increased. The change in insulin is then reset to zero and the program returns to the main rou~ine.
The steps sho~ln in Figs. 8E-8F are executed each time after the patient is prompted to take a dose of insulin and has entered the actual amount taken. The program module subfunction illustrated in steps 770-7~J:
checks the patient's data entry for possible keying errors and to notify the patient if he has taken a non-prescribed dose of insulin. In step 770, the insulintaken is the amount the patient keyed in before he pressed ENTER. In the following steps, this amount is compared to the amount of insulin actually prescribed by the program.

~3~3~;i -5~-In step 772, if the insulin prescribed is not more than 8 units, or the difference (ab501ute value) between the insulin taken and that prescribed is not more than 2 units, then the program module skips steps 774-778. If both of these conditions are met, however, then steps 774-7~6 are executed for possible keying errors by the patient.
Steps 774 and 778 determine whether the amount of insulin taken was 25% more or less than that pre-scribed. If so, then the appropriate message is dis--played, ei-ther "INSULIN DOSE GREATER THAN 125% EXPECTED"
(step 77G) or "INSU~IN DOSE LESS THAN 75~ EXPECTED"
(step 780). The patient is then asked whether the amount he entered is actually the amount taken in step 784. If the response is NO, indicating the patient has made an error, the monitor display reprompts the patient in step 736 with the correct dose of insulin and allows the patient to re-enter the correct amount. The steps beginning with step 770 are then reexecuted to insure that no additional error is maae. If the answer to step 784 is YES, then the program continues to step 788 (Fig.
8F~. Similarly, in step 782, if this is an unscheduled (UNS) entry and the amount of insulin taken is greater than 9 units, the patient is given a chance to correct a possible mistake in step 784.
Steps 788-792 (Fig. 8F) notify the patient if a non-prescribed dose is taken. If the entry i9 unsche-duled (UNS) in step 788, then the program module skips the next two steps. Otherwise, in step 790, the program checks to see whether the difference between the insulin taken and that prescribed is more than one unit. If so, then the message "NON-RX'D INSU~IN TAKEN" (step 792) is displayed. The program -then returns to either the main ~3~

routine (Fig. 8A) of the insulin recording/administra-tion program module or the appropriate step in the insu-lin computation submodule (Figs. 8B-8D).
It will be apparent to those skilled in the art that the various modifications can be made to the home monitor system of the instant invention without depart-ing from the scope or spirit of the invention, and it is intended that the present invention cover modifications and variations of the system provided they come within the scope of the appendant claims and their equivalents.

Claims (21)

1. A monitor system adapted for use by patients afflicted with diabetes mellitus, comprising:
a reflectance photometer for measuring blood glucose values;
circuit means coupled to said reflectance photo-meter for converting the output from said reflectance photometer to glucose data; and monitor means coupled to said circuit for storing said glucose data, for entering and storing administered insulin data, and for calculating and spe-cifying a recommended insulin dose based at least in part upon said measured glucose data and said admi-nistered insulin data.
2. The monitor system as set forth in Claim 1 wherein said circuit further comprises:
analog to digital converter means included in said circuit for generating said glucose data; and a data mulitplexer coupled to the output of said analog to digital converter and having an output coupled to said monitor means, for controlling the input/output between said analog to digital converter and said moni-tor means.
3. The monitor system as set forth in Claim 2 wherein said circuit further comprises an alarm/timer coupled to said data multiplexer, said data multiplexer further controlling the input-output between said alarm/
timer and said monitor means.
4. The monitor system as set forth in Claim 3 wherein said circuit further comprises a serial data port coupled to said data multiplexer, said data multiplexer further controlling the input/output between said alarm/timer and said monitor means.
5. A monitor system adapted for use by a patient afflicted with diabetes mellitus, comprising:
means for measuring blood glucose values and for generating blood glucose data in response to measuring said blood glucose values;
monitor means, connected to said measuring means and capable of receiving, storing and evaluating data, for (a) receiving and storing said blood glucose data, (b) receiving and storing physician-supplied data, (c) prompting and receiving patient input into the monitor means at periodic times of patient data relating to diet, exercise, emotional stress and symptoms of hypoglycemia and other illness experienced by the patient during c preceding time period, (d) receiving and storing the patient data supplied by the patient, and (e) generating recommendations relative to patient insulin dosage based at least in part upon the received blood glucose data, physician data and patient data.
6. The monitor system as set forth in Claim 5 wherein said measuring means includes:
reflectance photometer means for measuring blood glucose values; and circuit means coupled to said reflectance photometer means for converting the output signals from said reflectance photometer means to glucose data.
7. The monitor system as set forth in Claim 5 wherein said patient data includes diet data.
8. The monitor system as set forth in Claim 5 wherein said patient data includes exercise data.
9. The monitor system as set forth in Claim 5 wherein said patient data includes stress data.
10. The monitor system as set forth in Claim 5 wherein said patient data includes illness data.
11. The monitor system as set forth in Claim 5 wherein said patient data includes self report of hypoglycemic symptoms and/or insulin reactions and/or previously unentered measures of low blood sugar.
12. The monitor system as set forth in Claim 5 wherein the recommendations generated by said monitor means include a base insulin adjustment recommendation based at least in part upon said glucose data and said patient data stored in said monitor means over a prescribed number of days.
13. The monitor system as set forth in Claim 5 wherein the recommendations generated by said monitor means include a supplemental insulin dose recommendation based at least in part upon said patient data and said glucose data stored in said monitor means.
14. The monitor system as set forth in Claim 5 and further comprising:
computer means for at desired times receiving glucose data and patient data from said monitor means and for transmitting a physician insulin prescription to said monitor means;
and communication linkage means for at said times establishing a communication linkage between said computer means and said monitor means.
15. The monitor system as set forth in Claim 14 wherein said linkage means includes modems associated with said monitor means and said computer means for receiving and transmitting data therebetween.
16. A method for monitoring diabetes mellitus having a monitor apparatus storing physician assessment parameters and prescription data, a blood glucose measuring device coupled to the monitor apparatus, a computer located remotely from the monitor apparatus and connected thereto over a communication channel, said diabetes monitoring method comprising the steps of:

measuring blood glucose values with said blood glucose measuring device;
storing said blood glucose values as glucose data in said monitor apparatus;
inputting patient data into said monitor apparatus;
sending said glucose data and patient data to said computer over said communication channel;
evaluating said glucose data and patient data with said computer and transmitting to the monitor said physician assessment parameters;
storing said physician assessment parameters in said monitor apparatus;
using said monitor apparatus to generate insulin dosage recommendations based upon the therein stored physician assessment parameters, glucose data and patient data.
17. A method of monitoring diabetes mellitus with the use of a blood glucose measuring device and a thereto linked monitor apparatus capable of receiving and storing data, and of using the data to generate insulin dosage recommendations, comprising:
inputting initial physician-supplied data into the monitor;
supplying patient blood specimens at periodic times to the measuring device;
utilizing the measuring device to obtain blood glucose values from the samples, and to effect automatic input into the monitor of glucose data representative of the glucose values;
inputting into the monitor at periodic regular times patient data relating to diet, exercise, stress, and illness;
storing in the monitor the inputted physician, glucose and patient data;
utilizing the monitor to at times evaluate the data stored therein and to generate recommendations, based upon the evaluation, relative to patient insulin dosage.
18. A method of monitoring a patient having diabetes mellitus with the use of a blood glucose measuring device and a thereto linked monitor apparatus capable of receiving and storing data, and of using the data to generate insulin dosage recommendations, comprising:
(a) inputting initial physician-supplied data into the monitor apparatus;
(b) supplying patient blood specimens at periodic times to the measuring device;
(c) utilizing the measuring device to obtain blood glucose values from the specimens, and to effect automatic input into the monitor apparatus of glucose data representative of the glucose values;
(d) utilizing the monitor apparatus to prompt and receive patient input into the monitor apparatus at periodic regular times of patient data relating to diet, exercise, emotional stress, and symptoms of hypoglycemia and other illness actually experienced by the patient during a preceding time period;
(e) storing in the monitor apparatus the inputted physician, glucose and patient data;
(f) utilizing the monitor apparatus to at times evaluate the data stored therein and to generate recommendations, based upon the evaluation, relative to patient insulin dosage.
19. A method as in Claim 17 or Claim 18, wherein the symptoms of illness include fever.
20. A method as in Claim 17 or Claim 18, wherein the utilizing step includes generating a recommendation relative to a supplemental insulin dosage.
21. A method as in Claim 17 or Claim 18, wherein the blood glucose measuring device is a reflectance photometer, and the blood supplying step includes utilizing the monitor apparatus to prompt patient preparation of blood specimen test strips used in the photometer.
CA000537188A 1986-05-19 1987-05-14 Patient-operated glucose monitor and diabetes management system Expired - Lifetime CA1304135C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/864,506 US4731726A (en) 1986-05-19 1986-05-19 Patient-operated glucose monitor and diabetes management system
US864,506 1986-05-19

Publications (1)

Publication Number Publication Date
CA1304135C true CA1304135C (en) 1992-06-23

Family

ID=25343417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000537188A Expired - Lifetime CA1304135C (en) 1986-05-19 1987-05-14 Patient-operated glucose monitor and diabetes management system

Country Status (2)

Country Link
US (1) US4731726A (en)
CA (1) CA1304135C (en)

Families Citing this family (885)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US4803625A (en) * 1986-06-30 1989-02-07 Buddy Systems, Inc. Personal health monitor
US4935346A (en) * 1986-08-13 1990-06-19 Lifescan, Inc. Minimum procedure system for the determination of analytes
EP0290683A3 (en) * 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
US4933873A (en) * 1988-05-12 1990-06-12 Healthtech Services Corp. Interactive patient assistance device
US5142484A (en) * 1988-05-12 1992-08-25 Health Tech Services Corporation An interactive patient assistance device for storing and dispensing prescribed medication and physical device
GB2218831A (en) * 1988-05-17 1989-11-22 Mark John Newland Personal medical apparatus
US4975842A (en) * 1988-08-11 1990-12-04 Schering Corporation Electronic patient diary and patient monitoring process
US4947845A (en) * 1989-01-13 1990-08-14 Pacesetter Infusion, Ltd. Method of maximizing catheter longevity in an implantable medication infusion system
US4911168A (en) * 1989-01-13 1990-03-27 Pacesetter Infusion, Ltd. Method of screening and selecting intraperitoneal medication infusion pump candidates
CA2010165A1 (en) * 1989-03-13 1990-09-13 Richard L. Hurtle Compact semi-programmable device for reading reagent test strips and method relating thereto
US5388043A (en) * 1989-08-30 1995-02-07 Hettinger; Catherine A. Diet and behavioral control device
JPH0395435A (en) * 1989-09-08 1991-04-19 Terumo Corp Measuring apparatus
AU635314B2 (en) * 1989-09-08 1993-03-18 Terumo Kabushiki Kaisha Measuring apparatus
CA1323922C (en) * 1989-09-26 1993-11-02 William Fang Personal health monitor enclosure
US5197632A (en) * 1989-09-29 1993-03-30 Healthtech Services Corp. Interactive medication delivery system for individual pills and caplets
US5148944A (en) * 1989-09-29 1992-09-22 Health Tech Services Corporation Interactive medication delivery system for individual pills and caplets
US5335816A (en) * 1989-09-29 1994-08-09 Healthtech Services Corporation Interactive medication delivery system for medication prepackaged in blister packs
US5036462A (en) * 1989-09-29 1991-07-30 Healthtech Services Corp. Interactive patient assistance and medication delivery systems responsive to the physical environment of the patient
US5102008A (en) * 1989-09-29 1992-04-07 Healthtech Services Corporation Interactive medication delivery system for pills and caplets prepackaged on strips
US5126957A (en) * 1989-09-29 1992-06-30 Health Tech Services Corp. Interactive medication delivery system
CA1317636C (en) * 1989-09-29 1993-05-11 Buddy Systems, Inc. System and method for power supply preservation in a personal health monitor
US5084828A (en) * 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5230441A (en) * 1989-09-29 1993-07-27 Healthtech Services Corp. Interactive medication delivery system for pills
US5036852A (en) * 1989-12-08 1991-08-06 Leishman Mark L Medical equipment monitor apparatus and method
CA1317922C (en) * 1990-01-05 1993-05-18 James Varelis Ecg cable storage means in a personal health monitor
IL98203A (en) * 1990-06-20 1996-06-18 Bayer Ag Portable electronic logbook and method of storing and displaying data
US5251126A (en) * 1990-10-29 1993-10-05 Miles Inc. Diabetes data analysis and interpretation method
AU1257392A (en) * 1991-01-11 1992-08-17 Health Innovations Inc. Method and apparatus to control diet and weight using human behavior modification techniques
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
JPH04278450A (en) 1991-03-04 1992-10-05 Adam Heller Biosensor and method for analyzing subject
US5258314A (en) * 1991-03-18 1993-11-02 Paradigm Biotechnologies Partnership Microprocessor-based biomedical monitoring apparatus and method
FR2691820A1 (en) * 1992-05-26 1993-12-03 De Wailly Alain Portable insulin dosage calculator - has glycaemia monitor with information storage systems allowing optimum dose to be calculate
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
US5307263A (en) * 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US8626521B2 (en) * 1997-11-21 2014-01-07 Robert Bosch Healthcare Systems, Inc. Public health surveillance system
US7970620B2 (en) * 1992-11-17 2011-06-28 Health Hero Network, Inc. Multi-user remote health monitoring system with biometrics support
US5832448A (en) * 1996-10-16 1998-11-03 Health Hero Network Multiple patient monitoring system for proactive health management
US6196970B1 (en) * 1999-03-22 2001-03-06 Stephen J. Brown Research data collection and analysis
US9215979B2 (en) * 1992-11-17 2015-12-22 Robert Bosch Healthcare Systems, Inc. Multi-user remote health monitoring system
US8078407B1 (en) 1997-03-28 2011-12-13 Health Hero Network, Inc. System and method for identifying disease-influencing genes
US20010011224A1 (en) * 1995-06-07 2001-08-02 Stephen James Brown Modular microprocessor-based health monitoring system
US7624028B1 (en) * 1992-11-17 2009-11-24 Health Hero Network, Inc. Remote health monitoring and maintenance system
US20030212579A1 (en) * 2002-05-08 2003-11-13 Brown Stephen J. Remote health management system
US20070299321A1 (en) * 1992-11-17 2007-12-27 Brown Stephen J Method and apparatus for remote health monitoring and providing health related information
US8095340B2 (en) 1992-11-17 2012-01-10 Health Hero Network, Inc. Home power management system
US8078431B2 (en) 1992-11-17 2011-12-13 Health Hero Network, Inc. Home power management system
US20040019259A1 (en) * 1992-11-17 2004-01-29 Brown Stephen J. Remote monitoring and data management platform
WO2001037174A1 (en) * 1992-11-17 2001-05-25 Health Hero Network, Inc. Method and system for improving adherence with a diet program or other medical regimen
US7613590B2 (en) * 1992-11-17 2009-11-03 Health Hero Network, Inc. Modular microprocessor-based power tool system
US8027809B2 (en) 1992-11-17 2011-09-27 Health Hero Network, Inc. Home power management system
US6330426B2 (en) * 1994-05-23 2001-12-11 Stephen J. Brown System and method for remote education using a memory card
US7941326B2 (en) * 2001-03-14 2011-05-10 Health Hero Network, Inc. Interactive patient communication development system for reporting on patient healthcare management
US8635085B2 (en) * 1992-11-17 2014-01-21 Robert Bosch Gmbh Multi-user remote health monitoring system with biometrics support
US5956501A (en) * 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5960403A (en) * 1992-11-17 1999-09-28 Health Hero Network Health management process control system
US5951300A (en) * 1997-03-10 1999-09-14 Health Hero Network Online system and method for providing composite entertainment and health information
US6968375B1 (en) * 1997-03-28 2005-11-22 Health Hero Network, Inc. Networked system for interactive communication and remote monitoring of individuals
US5371687A (en) * 1992-11-20 1994-12-06 Boehringer Mannheim Corporation Glucose test data acquisition and management system
US6261235B1 (en) * 1993-01-07 2001-07-17 Seiko Epson Corporation Diagnostic apparatus for analyzing arterial pulse waves
AU7092294A (en) * 1993-04-30 1994-11-21 Arnold J Goldman Personalized method and system for storage, communication, analysis and processing of health-related data
US5837546A (en) * 1993-08-24 1998-11-17 Metrika, Inc. Electronic assay device and method
GB2282906B (en) 1993-10-13 1996-11-06 Dataquill Ltd Data enty systems
US5660176A (en) * 1993-12-29 1997-08-26 First Opinion Corporation Computerized medical diagnostic and treatment advice system
USRE43433E1 (en) 1993-12-29 2012-05-29 Clinical Decision Support, Llc Computerized medical diagnostic and treatment advice system
US5935060A (en) * 1996-07-12 1999-08-10 First Opinion Corporation Computerized medical diagnostic and treatment advice system including list based processing
US6206829B1 (en) * 1996-07-12 2001-03-27 First Opinion Corporation Computerized medical diagnostic and treatment advice system including network access
US8015033B2 (en) * 1994-04-26 2011-09-06 Health Hero Network, Inc. Treatment regimen compliance and efficacy with feedback
USD378612S (en) * 1995-05-23 1997-03-25 Lifescan, Inc. Blood glucose meter
US7635597B2 (en) 1995-08-09 2009-12-22 Bayer Healthcare Llc Dry reagent particle assay and device having multiple test zones and method therefor
US5665215A (en) * 1995-09-25 1997-09-09 Bayer Corporation Method and apparatus for making predetermined events with a biosensor
US5836312A (en) * 1996-01-02 1998-11-17 Moore; Steven Jerome Computer-assisted system and method for adjudging the effect of consumable intakes on physiological parameters
FI118509B (en) * 1996-02-12 2007-12-14 Nokia Oyj A method and apparatus for predicting blood glucose levels in a patient
US7305348B1 (en) 1996-02-20 2007-12-04 Health Hero Network, Inc. Aggregating and pooling health related information in a communication system with feedback
US20010044588A1 (en) * 1996-02-22 2001-11-22 Mault James R. Monitoring system
US8079953B2 (en) * 1996-06-17 2011-12-20 Cybernet Systems Corporation General-purpose medical instrumentation
US6050940A (en) 1996-06-17 2000-04-18 Cybernet Systems Corporation General-purpose medical instrumentation
US5954640A (en) * 1996-06-27 1999-09-21 Szabo; Andrew J. Nutritional optimization method
DE19632371A1 (en) * 1996-08-10 1998-05-20 Eckhard Dipl Phys D Salzsieder Method and arrangement for determining individual-specific insulin activity-equivalent physical activity
DE19634577A1 (en) * 1996-08-27 1998-03-05 Eckhard Dipl Phys D Salzsieder Method and arrangement for determining individual-specific daily profiles of blood sugar concentration, insulin activity and food absorption
ATE230115T1 (en) * 1996-10-30 2003-01-15 Amira Medical SYCRONIZED ANALYTE TEST SYSTEM
US6039688A (en) * 1996-11-01 2000-03-21 Salus Media Inc. Therapeutic behavior modification program, compliance monitoring and feedback system
US7590549B2 (en) * 1996-12-23 2009-09-15 Health Hero Network, Inc. Network media access control system for encouraging patient compliance with a treatment plan
US6032119A (en) 1997-01-16 2000-02-29 Health Hero Network, Inc. Personalized display of health information
ES2124186B1 (en) * 1997-01-20 1999-08-01 Carpe Diem Salud S L SECTION AND TELEMATIC CONTROL SYSTEM OF PHYSIOLOGICAL PARAMETERS OF PATIENTS.
US20050101032A1 (en) * 1997-02-10 2005-05-12 Metrika, Inc. Assay device, composition, and method of optimizing assay sensitivity
US7899511B2 (en) * 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US20050033132A1 (en) * 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US7657297B2 (en) * 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
IL131873A0 (en) * 1997-03-13 2001-03-19 First Opinion Corp Disease management system
US5997475A (en) * 1997-08-18 1999-12-07 Solefound, Inc. Device for diabetes management
US6269314B1 (en) * 1997-08-19 2001-07-31 Omron Corporation Blood sugar measuring device
WO1999023597A2 (en) * 1997-10-31 1999-05-14 Amira Medical Analyte concentration information collection and communication s ystem
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US7494816B2 (en) 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
US7407811B2 (en) * 1997-12-22 2008-08-05 Roche Diagnostics Operations, Inc. System and method for analyte measurement using AC excitation
US7390667B2 (en) * 1997-12-22 2008-06-24 Roche Diagnostics Operations, Inc. System and method for analyte measurement using AC phase angle measurements
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6024699A (en) 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
DE19814219A1 (en) * 1998-03-31 1999-10-07 Roche Diagnostics Gmbh Insulin medication control procedures
JPH11296598A (en) * 1998-04-07 1999-10-29 Seizaburo Arita System and method for predicting blood-sugar level and record medium where same method is recorded
US6835175B1 (en) 1998-04-10 2004-12-28 Proactive Metabolics Co. Medical devices for contemporaneous decision support in metabolic control
US6368272B1 (en) 1998-04-10 2002-04-09 Proactive Metabolics Company Equipment and method for contemporaneous decision supporting metabolic control
US7647237B2 (en) * 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20060019404A1 (en) * 1998-05-06 2006-01-26 Blatt Joel M Quantitative assay with extended dynamic range
US8882666B1 (en) 1998-05-08 2014-11-11 Ideal Life Inc. Personal health monitoring and/or communication system
EP1093343A4 (en) * 1998-07-13 2005-04-27 Los Angeles Childrens Hospital Non-invasive glucose monitor
US7398119B2 (en) 1998-07-13 2008-07-08 Childrens Hospital Los Angeles Assessing blood brain barrier dynamics or identifying or measuring selected substances, including ethanol or toxins, in a subject by analyzing Raman spectrum signals
US6558320B1 (en) * 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US8521546B2 (en) * 1998-09-25 2013-08-27 Health Hero Network Dynamic modeling and scoring risk assessment
EP1119285A1 (en) * 1998-10-08 2001-08-01 Minimed Inc. Telemetered characteristic monitor system
US7766873B2 (en) 1998-10-29 2010-08-03 Medtronic Minimed, Inc. Method and apparatus for detecting occlusions in an ambulatory infusion pump
US7621893B2 (en) * 1998-10-29 2009-11-24 Medtronic Minimed, Inc. Methods and apparatuses for detecting occlusions in an ambulatory infusion pump
US6188648B1 (en) 1998-11-03 2001-02-13 Toni L. Olsen Diabetic care overview wristwatch
US6602469B1 (en) 1998-11-09 2003-08-05 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
DK1144028T3 (en) 1998-11-30 2004-10-18 Novo Nordisk As A system for assisting a user during medical self-treatment, wherein said self-treatment comprises a plurality of actions
US20050086082A1 (en) * 1999-01-21 2005-04-21 Patient Care Technologies Portable health assistant
WO2000057774A1 (en) 1999-03-29 2000-10-05 Avocet Medical, Inc. Meter with integrated database and simplified telemedicine capability
US6367475B1 (en) 1999-04-02 2002-04-09 Korr Medical Technologies, Inc. Respiratory flow meter and methods of use
US20080201168A1 (en) * 1999-05-03 2008-08-21 Brown Stephen J Treatment regimen compliance and efficacy with feedback
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
AU5490600A (en) * 1999-06-18 2001-01-09 Spectrx, Inc. System and method for monitoring glucose to assist in weight management and fitness training
US6277071B1 (en) 1999-06-25 2001-08-21 Delphi Health Systems, Inc. Chronic disease monitor
WO2001006429A1 (en) * 1999-07-15 2001-01-25 Shea Robert S Method of sequencing chronic disease testing, reporting and evaluation
US6923763B1 (en) 1999-08-23 2005-08-02 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
EP1217942A1 (en) 1999-09-24 2002-07-03 Healthetech, Inc. Physiological monitor and associated computation, display and communication unit
US6535523B1 (en) * 1999-09-30 2003-03-18 Qualcomm Incorporated System and method for persistence vector based rate assignment
JP2004513669A (en) 1999-10-08 2004-05-13 ヘルセテック インコーポレイテッド Integrated calorie management system
US6925393B1 (en) * 1999-11-18 2005-08-02 Roche Diagnostics Gmbh System for the extrapolation of glucose concentration
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6980958B1 (en) 2000-01-11 2005-12-27 Zycare, Inc. Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients
DE10006044A1 (en) * 2000-02-10 2001-08-16 Roche Diagnostics Gmbh System, useful for administering hormone for blood glucose regulation of patient, comprises regulation unit with controller for processing measured data, and device for administering hormone
UA73967C2 (en) * 2000-02-14 2005-10-17 First Opinion Corp Structure-based automatic processing for diagnostics (variants)
US20030060765A1 (en) * 2000-02-16 2003-03-27 Arthur Campbell Infusion device menu structure and method of using the same
US20010037217A1 (en) * 2000-03-21 2001-11-01 Daniel Abensour Method to determine insulin dosage requirements via a diabetic management internet web site which is also telephony accessible including extensions to general diet management
IL151720A0 (en) * 2000-03-29 2003-04-10 Univ Virginia Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US20040172283A1 (en) * 2003-02-09 2004-09-02 Vanderveen Timothy W. Medication management and event logger and analysis system
US9069887B2 (en) 2000-05-18 2015-06-30 Carefusion 303, Inc. Patient-specific medication management system
US7860583B2 (en) 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
AU2001261723B2 (en) * 2000-05-18 2007-10-25 Aesynt Incorporated Distributed remote asset and medication management drug delivery system
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US20050171815A1 (en) * 2003-12-31 2005-08-04 Vanderveen Timothy W. Centralized medication management system
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
US6482158B2 (en) 2000-05-19 2002-11-19 Healthetech, Inc. System and method of ultrasonic mammography
EP1284642A4 (en) * 2000-05-25 2005-03-09 Healthetech Inc Physiological monitoring using wrist-mounted device
US20030226695A1 (en) * 2000-05-25 2003-12-11 Mault James R. Weight control method using physical activity based parameters
WO2002100266A1 (en) * 2000-06-13 2002-12-19 Edward Henry Mathews A dietary system: 'blood sugar predicting system'
AU2001272009A1 (en) * 2000-06-16 2001-12-24 Healthetech, Inc. Speech recognition capability for a personal digital assistant
US20020019752A1 (en) * 2000-06-23 2002-02-14 Isamu Takase System for therapy management and terminal used therefor
JP2004501380A (en) * 2000-06-26 2004-01-15 ボストン メディカル テクノロジーズ インコーポレイテッド Glucose measurement system
ATE438338T1 (en) * 2000-06-30 2009-08-15 Becton Dickinson Co HEALTH AND SICKNESS MANAGEMENT SYSTEM FOR IMPROVED PATIENT CARE
US20020026111A1 (en) * 2000-08-28 2002-02-28 Neil Ackerman Methods of monitoring glucose levels in a subject and uses thereof
AU2001288902A1 (en) * 2000-09-07 2002-03-22 Healthetech, Inc. Portable computing apparatus particularly useful in a weight management program
US6607387B2 (en) 2000-10-30 2003-08-19 Healthetech, Inc. Sensor system for diagnosing dental conditions
US20020055857A1 (en) * 2000-10-31 2002-05-09 Mault James R. Method of assisting individuals in lifestyle control programs conducive to good health
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
EP1357490A4 (en) * 2000-12-22 2006-10-25 Arkray Inc Examination management device
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6961599B2 (en) * 2001-01-09 2005-11-01 Childrens Hospital Los Angeles Identifying or measuring selected substances or toxins in a subject using resonant raman signals
MXPA02009916A (en) * 2001-02-08 2004-09-06 Inverness Medical Ltd A personal condition management system.
US20010044732A1 (en) * 2001-06-26 2001-11-22 Maus Christopher T. Mobile data management system
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
WO2002078512A2 (en) 2001-04-02 2002-10-10 Therasense, Inc. Blood glucose tracking apparatus and methods
JP4498636B2 (en) * 2001-04-27 2010-07-07 日本サーモスタット株式会社 Thermostat device
US8034026B2 (en) * 2001-05-18 2011-10-11 Deka Products Limited Partnership Infusion pump assembly
MXPA03010576A (en) * 2001-05-18 2004-05-27 Deka Products Lp Infusion set for a fluid pump.
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
DE60238119D1 (en) 2001-06-12 2010-12-09 Pelikan Technologies Inc ELECTRIC ACTUATOR ELEMENT FOR A LANZETTE
ES2336081T3 (en) 2001-06-12 2010-04-08 Pelikan Technologies Inc. SELF-OPTIMIZATION PUNCTURE DEVICE WITH MEANS OF ADAPTATION TO TEMPORARY VARIATIONS IN CUTANEOUS PROPERTIES.
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US20030208113A1 (en) * 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US20030130595A1 (en) * 2001-08-13 2003-07-10 Mault James R. Health improvement systems and methods
US20030130567A1 (en) * 2002-01-09 2003-07-10 Mault James R. Health-related devices and methods
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US6840904B2 (en) * 2001-10-11 2005-01-11 Jason Goldberg Medical monitoring device and system
US6966880B2 (en) * 2001-10-16 2005-11-22 Agilent Technologies, Inc. Universal diagnostic platform
US7369919B2 (en) * 2001-11-30 2008-05-06 Vonk Glenn P Medication adherence system
US7399277B2 (en) * 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20050027182A1 (en) * 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20080255438A1 (en) * 2001-12-27 2008-10-16 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7022072B2 (en) * 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US10080529B2 (en) 2001-12-27 2018-09-25 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20030130874A1 (en) * 2002-01-07 2003-07-10 Borenstein Jeffrey Andrew Medication-partnership program
US20030216628A1 (en) * 2002-01-28 2003-11-20 Bortz Jonathan David Methods and systems for assessing glycemic control using predetermined pattern label analysis of blood glucose readings
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20030152607A1 (en) * 2002-02-13 2003-08-14 Mault James R. Caloric management system and method with voice recognition
US20040034288A1 (en) * 2002-02-20 2004-02-19 Hennessy Gary R. Chronic disease outcomes education and communication system
US8504179B2 (en) * 2002-02-28 2013-08-06 Smiths Medical Asd, Inc. Programmable medical infusion pump
US8250483B2 (en) * 2002-02-28 2012-08-21 Smiths Medical Asd, Inc. Programmable medical infusion pump displaying a banner
US20050108061A1 (en) * 2002-03-15 2005-05-19 Peter Meserol Medical management system and method
US20030229517A1 (en) * 2002-03-15 2003-12-11 Peter Meserol Medical management system and method
US20030192688A1 (en) * 2002-04-10 2003-10-16 Thomson Michael A. Tubing saver rotator and method for using same
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
WO2003090614A1 (en) * 2002-04-25 2003-11-06 Matsushita Electric Industrial Co., Ltd. Dosage determination supporting device, injector, and health management supporting system
WO2003094074A1 (en) * 2002-05-02 2003-11-13 Lifestream Technologies, Inc. Computerized information processing and retrieval system
US20030212344A1 (en) * 2002-05-09 2003-11-13 Vadim Yuzhakov Physiological sample collection devices and methods of using the same
US20030143113A2 (en) * 2002-05-09 2003-07-31 Lifescan, Inc. Physiological sample collection devices and methods of using the same
US20030211619A1 (en) * 2002-05-09 2003-11-13 Lorin Olson Continuous strip of fluid sampling and testing devices and methods of making, packaging and using the same
US7060192B2 (en) * 2002-05-09 2006-06-13 Lifescan, Inc. Methods of fabricating physiological sample collection devices
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
GB2389419B (en) * 2002-06-05 2006-02-22 Diabetes Diagnostics Inc Analyte testing device
US7278983B2 (en) * 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
US8512276B2 (en) 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US20040068230A1 (en) * 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
EP2327359B1 (en) * 2002-08-13 2015-01-21 University Of Virginia Patent Foundation Method, system, and computer program product for processing of self-monitoring blood glucose (smbg) data to enhance diabetic self-management
US20070100666A1 (en) * 2002-08-22 2007-05-03 Stivoric John M Devices and systems for contextual and physiological-based detection, monitoring, reporting, entertainment, and control of other devices
WO2004023972A2 (en) 2002-09-11 2004-03-25 Becton, Dickinson And Company Monitoring blood glucose including convenient display of measurement values ________________________________________________________
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US6931328B2 (en) * 2002-11-08 2005-08-16 Optiscan Biomedical Corp. Analyte detection system with software download capabilities
US20040115754A1 (en) * 2002-12-11 2004-06-17 Umax Data Systems Inc. Method for establishing a long-term profile of blood sugar level aiding self-control of the same
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
TW200411178A (en) * 2002-12-31 2004-07-01 Veutron Corp Method for determining the resolution of blood glucose by using rising time curve
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US20050060194A1 (en) * 2003-04-04 2005-03-17 Brown Stephen J. Method and system for monitoring health of an individual
TW592667B (en) * 2003-04-04 2004-06-21 Veutron Corp Method for determining the resolution of blood glucose
US7587287B2 (en) 2003-04-04 2009-09-08 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US7134999B2 (en) * 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7260480B1 (en) 2003-04-07 2007-08-21 Health Hero Network, Inc. Method and system for integrating feedback loops in medical knowledge development and healthcare management
CA2522485A1 (en) * 2003-04-15 2004-10-28 Optiscan Biomedical Corporation Dual measurement analyte detection system
US20050038674A1 (en) * 2003-04-15 2005-02-17 Braig James R. System and method for managing a chronic medical condition
US7399276B1 (en) 2003-05-08 2008-07-15 Health Hero Network, Inc. Remote health monitoring system
US7780595B2 (en) 2003-05-15 2010-08-24 Clinical Decision Support, Llc Panel diagnostic method and system
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
ATE476137T1 (en) 2003-05-30 2010-08-15 Pelikan Technologies Inc METHOD AND DEVICE FOR INJECTING LIQUID
DK1633235T3 (en) 2003-06-06 2014-08-18 Sanofi Aventis Deutschland Apparatus for sampling body fluid and detecting analyte
US20050010444A1 (en) * 2003-06-06 2005-01-13 Iliff Edwin C. System and method for assisting medical diagnosis using an anatomic system and cause matrix
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7645373B2 (en) * 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7452457B2 (en) * 2003-06-20 2008-11-18 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7604721B2 (en) 2003-06-20 2009-10-20 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7597793B2 (en) * 2003-06-20 2009-10-06 Roche Operations Ltd. System and method for analyte measurement employing maximum dosing time delay
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US20050055243A1 (en) * 2003-06-30 2005-03-10 Dave Arndt Method and apparatus for managing data received from a medical device
US7695239B2 (en) * 2003-07-14 2010-04-13 Fortrend Engineering Corporation End effector gripper arms having corner grippers which reorient reticle during transfer
US8034294B1 (en) 2003-07-15 2011-10-11 Ideal Life, Inc. Medical monitoring/consumables tracking device
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005010518A1 (en) * 2003-07-23 2005-02-03 Dexcom, Inc. Rolled electrode array and its method for manufacture
US8423113B2 (en) * 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
JP4708342B2 (en) * 2003-07-25 2011-06-22 デックスコム・インコーポレーテッド Oxygen augmentation membrane system for use in implantable devices
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US7519408B2 (en) * 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8845536B2 (en) * 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9135402B2 (en) * 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8160669B2 (en) * 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US20070208245A1 (en) * 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US7933639B2 (en) 2003-08-01 2011-04-26 Dexcom, Inc. System and methods for processing analyte sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8060173B2 (en) 2003-08-01 2011-11-15 Dexcom, Inc. System and methods for processing analyte sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US20080119703A1 (en) * 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US8571880B2 (en) * 2003-08-07 2013-10-29 Ideal Life, Inc. Personal health management device, method and system
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US20050066335A1 (en) * 2003-09-23 2005-03-24 Robert Aarts System and method for exposing local clipboard functionality towards external applications
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US20050090607A1 (en) * 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
EP1683058A2 (en) * 2003-10-29 2006-07-26 Novo Nordisk A/S Medical advisory system
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
EP1680175B1 (en) * 2003-11-06 2019-06-05 LifeScan, Inc. Drug delivery pen with event notification means
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8615282B2 (en) 2004-07-13 2013-12-24 Dexcom, Inc. Analyte sensor
US8038593B2 (en) * 2003-12-05 2011-10-18 Carefusion 303, Inc. System and method for network monitoring of multiple medical devices
EP1709778A1 (en) * 2003-12-05 2006-10-11 Cardinal Health 303, Inc. Discovery and connection management with mobile systems manager
US20080197024A1 (en) * 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
US8425416B2 (en) * 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
EP1711790B1 (en) 2003-12-05 2010-09-08 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US8425417B2 (en) * 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364230B2 (en) * 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
EP2316331B1 (en) * 2003-12-09 2016-06-29 Dexcom, Inc. Signal processing for continuous analyte sensor
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US7637868B2 (en) * 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
RU2006132051A (en) 2004-02-06 2008-03-20 БАЙЕР ХЕЛТКЭР ЭлЭлСи (US) OXIDIZABLE COMPOUNDS AS AN INTERNAL STANDARD FOR BIOSENSORS AND METHOD OF APPLICATION
EP1718198A4 (en) 2004-02-17 2008-06-04 Therasense Inc Method and system for providing data communication in continuous glucose monitoring and management system
US8954336B2 (en) 2004-02-23 2015-02-10 Smiths Medical Asd, Inc. Server for medical device
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
WO2005103991A1 (en) * 2004-04-20 2005-11-03 Medwatchdog Kg Pocket-type medical monitoring and signaling device
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US20050245799A1 (en) * 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
WO2005113036A1 (en) * 2004-05-13 2005-12-01 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
SE528768C2 (en) * 2004-05-24 2007-02-13 Hemocue Ab Hand-held medical logging device and method
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
CA2858901C (en) 2004-06-04 2024-01-16 Carolyn Anderson Diabetes care host-client architecture and data management system
US20070100222A1 (en) * 2004-06-14 2007-05-03 Metronic Minimed, Inc. Analyte sensing apparatus for hospital use
US7569126B2 (en) 2004-06-18 2009-08-04 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US7556723B2 (en) * 2004-06-18 2009-07-07 Roche Diagnostics Operations, Inc. Electrode design for biosensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
US20080242961A1 (en) * 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US7344500B2 (en) * 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US9081879B2 (en) * 2004-10-22 2015-07-14 Clinical Decision Support, Llc Matrix interface for medical diagnostic and treatment advice system and method
US20060089540A1 (en) * 2004-10-27 2006-04-27 Alan Meissner Device for diabetes management
EP1815375A2 (en) * 2004-11-15 2007-08-08 Novo Nordisk A/S Method and apparatus for monitoring long term and short term effects of a treatment
US7303543B1 (en) 2004-12-03 2007-12-04 Medtronic Minimed, Inc. Medication infusion set
RU2430264C2 (en) * 2004-12-16 2011-09-27 Индепендент Нэчурэл Ресорсиз, Инк. Power system built around float-type pump
US7697967B2 (en) * 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
WO2006072035A1 (en) 2004-12-29 2006-07-06 Lifescan Scotland Limited Method of inputting data into an analyte testing device
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US8333714B2 (en) * 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US20090105569A1 (en) * 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
ITBO20050002A1 (en) * 2005-01-04 2006-07-05 Giacomo Vespasiani METHOD AND SYSTEM FOR INTERACTIVE MANAGEMENT OF DATA CONCERNING AN INSULIN THERAPY IN SELF-CONTROL FOR A DIABETIC PATIENT
US7704229B2 (en) * 2005-02-03 2010-04-27 Medtronic Minimed, Inc. Insertion device
US20060184104A1 (en) * 2005-02-15 2006-08-17 Medtronic Minimed, Inc. Needle guard
US8165893B1 (en) * 2005-02-16 2012-04-24 Ideal Life Inc. Medical monitoring and coordinated care system
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US20060235282A1 (en) * 2005-03-17 2006-10-19 Helen Wesolowski Methods for the treatment of mammals with abnormal glucose tolerance
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US8060174B2 (en) 2005-04-15 2011-11-15 Dexcom, Inc. Analyte sensing biointerface
GB0507838D0 (en) * 2005-04-18 2005-05-25 Epsom & St Helier University H A method of measuring the glomerular filtration rate of an human or animal patient, a self-use kit for providing blood samples for use in measuring glomerular
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7888125B2 (en) * 2005-05-09 2011-02-15 Theranos, Inc. Calibration of fluidic devices
EP1891561B1 (en) * 2005-05-17 2020-01-15 F. Hoffmann-La Roche AG Host apparatus and method providing calibration and reagent information to a measurement apparatus which makes use of a consumable reagent in a measuring process
US20070033074A1 (en) * 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20060272652A1 (en) * 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
EP1728468A1 (en) * 2005-06-04 2006-12-06 Roche Diagnostics GmbH Evaluation of blood glucose concentration values for adaptation of insulin dosage
AU2006254849A1 (en) * 2005-06-08 2006-12-14 Agamatrix, Inc. Data collection system and interface
US8251904B2 (en) * 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20070016449A1 (en) * 2005-06-29 2007-01-18 Gary Cohen Flexible glucose analysis using varying time report deltas and configurable glucose target ranges
US20090134181A1 (en) * 2005-07-13 2009-05-28 Vitality, Inc. Medication dispenser with automatic refill
US20070016443A1 (en) * 2005-07-13 2007-01-18 Vitality, Inc. Medication compliance systems, methods and devices with configurable and adaptable escalation engine
US20100270257A1 (en) * 2005-07-13 2010-10-28 Vitality, Inc. Medicine Bottle Cap With Electronic Embedded Curved Display
AR054851A1 (en) * 2005-07-20 2007-07-18 Bayer Healthcare Llc REGULATED AMPEROMETRY
US20070066956A1 (en) * 2005-07-27 2007-03-22 Medtronic Minimed, Inc. Systems and methods for entering temporary basal rate pattern in an infusion device
US20090227855A1 (en) * 2005-08-16 2009-09-10 Medtronic Minimed, Inc. Controller device for an infusion pump
US20070060870A1 (en) * 2005-08-16 2007-03-15 Tolle Mike Charles V Controller device for an infusion pump
US20070093786A1 (en) * 2005-08-16 2007-04-26 Medtronic Minimed, Inc. Watch controller for a medical device
US20070060869A1 (en) * 2005-08-16 2007-03-15 Tolle Mike C V Controller device for an infusion pump
US7737581B2 (en) 2005-08-16 2010-06-15 Medtronic Minimed, Inc. Method and apparatus for predicting end of battery life
EP1921980A4 (en) 2005-08-31 2010-03-10 Univ Virginia Improving the accuracy of continuous glucose sensors
US7713240B2 (en) 2005-09-13 2010-05-11 Medtronic Minimed, Inc. Modular external infusion device
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US8404100B2 (en) 2005-09-30 2013-03-26 Bayer Healthcare Llc Gated voltammetry
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7941200B2 (en) * 2005-12-08 2011-05-10 Roche Diagnostics Operations, Inc. System and method for determining drug administration information
WO2007120363A2 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care, Inc. Medical device insertion
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US20070173712A1 (en) * 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Method of and system for stabilization of sensors
US8114268B2 (en) * 2005-12-30 2012-02-14 Medtronic Minimed, Inc. Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US20070169533A1 (en) * 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Methods and systems for detecting the hydration of sensors
US7774038B2 (en) * 2005-12-30 2010-08-10 Medtronic Minimed, Inc. Real-time self-calibrating sensor system and method
US7985330B2 (en) 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
RU2477078C2 (en) * 2006-01-05 2013-03-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Method, system and software product for estimating changeability of glucose content in blood in case of diabetes by self-control data
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7736310B2 (en) * 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US7873949B2 (en) * 2006-02-08 2011-01-18 Microsoft Corporation In source code suppression of binary analysis
US10010669B2 (en) 2006-02-09 2018-07-03 Deka Products Limited Partnership Systems and methods for fluid delivery
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11027058B2 (en) 2006-02-09 2021-06-08 Deka Products Limited Partnership Infusion pump assembly
EP2335754B1 (en) 2006-02-09 2013-12-18 DEKA Products Limited Partnership Patch-sized fluid delivery systems
EP1818009A1 (en) * 2006-02-11 2007-08-15 Roche Diagnostics GmbH Portable analysis device with setting mode selection
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US7653425B2 (en) * 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US20080027292A1 (en) * 2006-04-10 2008-01-31 Rosman Paul M Computer-Implemented Method and Apparatus for Diabetes Management
US20070255126A1 (en) * 2006-04-28 2007-11-01 Moberg Sheldon B Data communication in networked fluid infusion systems
US20070253380A1 (en) * 2006-04-28 2007-11-01 James Jollota Data translation device with nonvolatile memory for a networked medical device system
US20070254593A1 (en) * 2006-04-28 2007-11-01 Medtronic Minimed, Inc. Wireless data communication for a medical device network that supports a plurality of data communication modes
US7942844B2 (en) * 2006-04-28 2011-05-17 Medtronic Minimed, Inc. Remote monitoring for networked fluid infusion systems
US8073008B2 (en) * 2006-04-28 2011-12-06 Medtronic Minimed, Inc. Subnetwork synchronization and variable transmit synchronization techniques for a wireless medical device network
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20070270677A1 (en) * 2006-05-22 2007-11-22 Steve Thuss Interactive device for monitoring and reporting glucose levels
US20070276197A1 (en) * 2006-05-24 2007-11-29 Lifescan, Inc. Systems and methods for providing individualized disease management
US20070288266A1 (en) * 2006-06-02 2007-12-13 Suzanne Sysko System and methods for chronic disease management and health assessment
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US20080177149A1 (en) * 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
US8965707B2 (en) 2006-08-03 2015-02-24 Smiths Medical Asd, Inc. Interface for medical infusion pump
US8435206B2 (en) * 2006-08-03 2013-05-07 Smiths Medical Asd, Inc. Interface for medical infusion pump
US8149131B2 (en) 2006-08-03 2012-04-03 Smiths Medical Asd, Inc. Interface for medical infusion pump
US8858526B2 (en) 2006-08-03 2014-10-14 Smiths Medical Asd, Inc. Interface for medical infusion pump
GB0616566D0 (en) * 2006-08-19 2006-09-27 Rolls Royce Plc An alloy and method of treating titanium aluminide
US8758238B2 (en) * 2006-08-31 2014-06-24 Health Hero Network, Inc. Health related location awareness
US7831287B2 (en) * 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8562528B2 (en) * 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8449464B2 (en) * 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
US8478377B2 (en) * 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US8275438B2 (en) * 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
WO2008052199A2 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care, Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US20080306353A1 (en) * 2006-11-03 2008-12-11 Douglas Joel S Calculation device for metabolic control of critically ill and/or diabetic patients
US20080113391A1 (en) * 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
US20080119705A1 (en) * 2006-11-17 2008-05-22 Medtronic Minimed, Inc. Systems and Methods for Diabetes Management Using Consumer Electronic Devices
US8540517B2 (en) * 2006-11-27 2013-09-24 Pharos Innovations, Llc Calculating a behavioral path based on a statistical profile
US8540515B2 (en) * 2006-11-27 2013-09-24 Pharos Innovations, Llc Optimizing behavioral change based on a population statistical profile
US8540516B2 (en) * 2006-11-27 2013-09-24 Pharos Innovations, Llc Optimizing behavioral change based on a patient statistical profile
US20080139910A1 (en) * 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
US20080154513A1 (en) * 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US20080214919A1 (en) * 2006-12-26 2008-09-04 Lifescan, Inc. System and method for implementation of glycemic control protocols
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
WO2008101172A2 (en) * 2007-02-16 2008-08-21 Ohio University System and method for managing diabetes
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US10872686B2 (en) 2007-02-22 2020-12-22 WellDoc, Inc. Systems and methods for disease control and management
US10860943B2 (en) 2007-02-22 2020-12-08 WellDoc, Inc. Systems and methods for disease control and management
US9754077B2 (en) 2007-02-22 2017-09-05 WellDoc, Inc. Systems and methods for disease control and management
US20110166698A1 (en) * 2007-02-28 2011-07-07 Anthony Vallone Delivery of medication regimen in medication reminder device
US8081064B1 (en) 2007-02-28 2011-12-20 Anthony Vallone Method for facilitating compliance with medication regimen
US7957984B1 (en) * 2007-02-28 2011-06-07 Anthony Vallone Device for facilitating compliance with medication regimen
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8758245B2 (en) * 2007-03-20 2014-06-24 Lifescan, Inc. Systems and methods for pattern recognition in diabetes management
US20080235053A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Communication medium for diabetes management
US20080234943A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
WO2008130898A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683930A1 (en) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130897A2 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683721C (en) 2007-04-14 2017-05-23 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) * 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
WO2008150917A1 (en) * 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
US20080300572A1 (en) * 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US20080306434A1 (en) 2007-06-08 2008-12-11 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
AU2008265542B2 (en) 2007-06-21 2014-07-24 Abbott Diabetes Care Inc. Health monitor
US8597188B2 (en) 2007-06-21 2013-12-03 Abbott Diabetes Care Inc. Health management devices and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US7768386B2 (en) * 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
AU2008284273A1 (en) * 2007-08-08 2009-02-12 Kemeta, Llc Biosensor system with a multifunctional portable electronic device
GB0716427D0 (en) * 2007-08-23 2007-10-03 Smartsensor Telemed Ltd Glucose tolerance test device
US7998069B2 (en) * 2007-09-11 2011-08-16 Roche Diagnostics Operations, Inc. Mask algorithms for health management systems
US9452258B2 (en) 2007-10-09 2016-09-27 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
WO2009049245A1 (en) * 2007-10-11 2009-04-16 Optiscan Biomedical Corporation Synchronization and configuration of patient monitoring devices
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US20090112626A1 (en) * 2007-10-30 2009-04-30 Cary Talbot Remote wireless monitoring, processing, and communication of patient data
US8882668B2 (en) 2007-11-19 2014-11-11 Elizabeth S. Thompson Method and process for body composition management
US8103241B2 (en) * 2007-12-07 2012-01-24 Roche Diagnostics Operations, Inc. Method and system for wireless device communication
US8019721B2 (en) 2007-12-07 2011-09-13 Roche Diagnostics Operations, Inc. Method and system for enhanced data transfer
US20090150877A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Data driven communication protocol grammar
US8078592B2 (en) 2007-12-07 2011-12-13 Roche Diagnostics Operations, Inc. System and method for database integrity checking
US8402151B2 (en) 2007-12-07 2013-03-19 Roche Diagnostics Operations, Inc. Dynamic communication stack
US7979136B2 (en) * 2007-12-07 2011-07-12 Roche Diagnostics Operation, Inc Method and system for multi-device communication
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US8313467B2 (en) 2007-12-27 2012-11-20 Medtronic Minimed, Inc. Reservoir pressure equalization systems and methods
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
RU2510758C2 (en) * 2007-12-31 2014-04-10 Дека Продактс Лимитед Партнершип Infusion pump assembly
US8414563B2 (en) * 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US20090177147A1 (en) * 2008-01-07 2009-07-09 Michael Blomquist Insulin pump with insulin therapy coaching
WO2009105337A2 (en) * 2008-02-20 2009-08-27 Dexcom, Inc. Continuous medicament sensor system for in vivo use
CA2715628A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US20090240127A1 (en) * 2008-03-20 2009-09-24 Lifescan, Inc. Methods of determining pre or post meal time slots or intervals in diabetes management
US20090240702A1 (en) 2008-03-21 2009-09-24 Computerized Screening, Inc. Community based managed health kiosk and research database system
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9341614B2 (en) * 2008-04-04 2016-05-17 Hygieia, Inc. Apparatus and methods for taking blood glucose measurements and recommending insulin doses
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US10624577B2 (en) 2008-04-04 2020-04-21 Hygieia, Inc. Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
CN103400028B (en) 2008-04-04 2017-04-12 海吉雅有限公司 Device for optimizing patient's insulin dosage regimen
EP3659628A1 (en) 2008-04-10 2020-06-03 Abbott Diabetes Care, Inc. Method and system for sterilizing an analyte sensor
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US8133197B2 (en) 2008-05-02 2012-03-13 Smiths Medical Asd, Inc. Display for pump
US20100256047A1 (en) * 2009-04-03 2010-10-07 Lifescan, Inc. Analyte Measurement and Management Device and Associated Methods
US20090281393A1 (en) * 2008-05-08 2009-11-12 Putnam Technical Group, Inc. Method and apparatus for administering and monitoring patient treatment
US9295786B2 (en) 2008-05-28 2016-03-29 Medtronic Minimed, Inc. Needle protective device for subcutaneous sensors
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
IT1396465B1 (en) * 2008-07-10 2012-12-14 B G Informatica S R L METHOD FOR THE DEFINITION AND INTERACTIVE MANAGEMENT OF A TREATMENT FOR THE CONTROL OF GLYCEMIC RATE IN THE DIABETIC PATIENT AND INTEGRATED DEVICE THAT IMPLEMENTS THIS METHOD
WO2010009172A1 (en) 2008-07-14 2010-01-21 Abbott Diabetes Care Inc. Closed loop control system interface and methods
CA2731031A1 (en) * 2008-07-18 2010-01-21 Lifescan, Inc. Analyte measurement and management device and associated methods
US8423378B1 (en) 2008-07-24 2013-04-16 Ideal Life, Inc. Facilitating health care management of subjects
US8454904B2 (en) * 2008-07-29 2013-06-04 Roche Diagnostics Operations, Inc. Biosensor container
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8589178B2 (en) * 2008-09-10 2013-11-19 Roche Diagnostics Operations, Inc. Extensible therapy delivery system and method thereof
WO2010033724A2 (en) 2008-09-19 2010-03-25 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9180245B2 (en) 2008-10-10 2015-11-10 Deka Products Limited Partnership System and method for administering an infusible fluid
US8066672B2 (en) 2008-10-10 2011-11-29 Deka Products Limited Partnership Infusion pump assembly with a backup power supply
US8262616B2 (en) * 2008-10-10 2012-09-11 Deka Products Limited Partnership Infusion pump assembly
US8223028B2 (en) 2008-10-10 2012-07-17 Deka Products Limited Partnership Occlusion detection system and method
US8708376B2 (en) * 2008-10-10 2014-04-29 Deka Products Limited Partnership Medium connector
US8016789B2 (en) * 2008-10-10 2011-09-13 Deka Products Limited Partnership Pump assembly with a removable cover assembly
US8267892B2 (en) 2008-10-10 2012-09-18 Deka Products Limited Partnership Multi-language / multi-processor infusion pump assembly
US8208973B2 (en) * 2008-11-05 2012-06-26 Medtronic Minimed, Inc. System and method for variable beacon timing with wireless devices
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
WO2010056718A2 (en) 2008-11-11 2010-05-20 Hygieia, Inc. Apparatus and system for diabetes management
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
EP4246522A3 (en) * 2008-12-23 2023-11-08 Roche Diabetes Care GmbH Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
US9918635B2 (en) * 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US10437962B2 (en) * 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US10456036B2 (en) * 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9330237B2 (en) 2008-12-24 2016-05-03 Medtronic Minimed, Inc. Pattern recognition and filtering in a therapy management system
US20100161346A1 (en) * 2008-12-24 2010-06-24 Kristen Getschmann Systems and Methods for Providing Bolus Dosage Recommendations
US20100185517A1 (en) * 2009-01-21 2010-07-22 Yahoo! Inc. User interface for interest-based targeted marketing
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
CN102369032B (en) 2009-02-04 2015-09-30 赛诺菲-安万特德国有限公司 For being provided for medical system and the method for the information of glycemic control
EP2393412B1 (en) 2009-02-04 2017-08-30 Sanofi-Aventis Deutschland GmbH Medical device and method for providing information for glycemic control
US8764425B2 (en) 2009-02-12 2014-07-01 Picolife Technologies, Llc Mold for making a membrane for use with a flow control system for a micropump
US8226905B2 (en) * 2009-02-18 2012-07-24 Richard Abdallah Blood glucose measurement device
EP2410910A4 (en) * 2009-03-27 2014-10-15 Dexcom Inc Methods and systems for promoting glucose management
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010121229A1 (en) 2009-04-16 2010-10-21 Abbott Diabetes Care Inc. Analyte sensor calibration management
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2424426B1 (en) 2009-04-29 2020-01-08 Abbott Diabetes Care, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
EP2425209A4 (en) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc Method and system for providing real time analyte sensor calibration with retrospective backfill
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US20100318424A1 (en) * 2009-06-12 2010-12-16 L2La, Llc System for Correlating Physiological and Environmental Conditions
US20100324932A1 (en) * 2009-06-19 2010-12-23 Roche Diagnostics Operations, Inc. Methods and systems for advising people with diabetes
US20100331652A1 (en) * 2009-06-29 2010-12-30 Roche Diagnostics Operations, Inc. Modular diabetes management systems
US9218453B2 (en) * 2009-06-29 2015-12-22 Roche Diabetes Care, Inc. Blood glucose management and interface systems and methods
WO2011002768A1 (en) * 2009-06-30 2011-01-06 Lifescan, Inc. Analyte testing method and system
EP2455875A3 (en) * 2009-06-30 2013-01-16 Lifescan Scotland Limited System and method for diabetes management
JP5654587B2 (en) * 2009-06-30 2015-01-14 ライフスキャン・インコーポレイテッドLifescan,Inc. Analyte test method and apparatus for calculating basal insulin therapy
US8613892B2 (en) 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
US20110009813A1 (en) * 2009-07-09 2011-01-13 Medtronic Minimed, Inc. Panning a display of a portable medical device
US20110006880A1 (en) * 2009-07-09 2011-01-13 Medtronic Minimed, Inc. Fingerprint-linked control of a portable medical device
US8344847B2 (en) 2009-07-09 2013-01-01 Medtronic Minimed, Inc. Coordination of control commands in a medical device system having at least one therapy delivery device and at least one wireless controller device
WO2011008966A2 (en) 2009-07-15 2011-01-20 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
EP4309580A3 (en) 2009-07-23 2024-02-28 Abbott Diabetes Care Inc. Continuous analyte measurement system
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
BR112012000220A2 (en) 2009-08-31 2020-12-22 Abbott Diabetes Care Inc. METHODS AND MEDICAL DEVICES
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011026053A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Displays for a medical device
US8487758B2 (en) * 2009-09-02 2013-07-16 Medtronic Minimed, Inc. Medical device having an intelligent alerting scheme, and related operating methods
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
US8545693B2 (en) * 2009-09-29 2013-10-01 Lifescan Scotland Limited Analyte measurment method and system
CA3077994C (en) * 2009-09-29 2022-06-21 Lifescan Scotland Limited Analyte testing method and device for diabetes management
WO2011041531A1 (en) 2009-09-30 2011-04-07 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
CN105825049A (en) 2009-10-19 2016-08-03 提拉诺斯公司 Integrated health data capture and analysis system
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8386042B2 (en) * 2009-11-03 2013-02-26 Medtronic Minimed, Inc. Omnidirectional accelerometer device and medical device incorporating same
US8574201B2 (en) 2009-12-22 2013-11-05 Medtronic Minimed, Inc. Syringe piston with check valve seal
US20110152970A1 (en) * 2009-12-23 2011-06-23 Medtronic Minimed, Inc. Location-based ranking and switching of wireless channels in a body area network of medical devices
US8755269B2 (en) * 2009-12-23 2014-06-17 Medtronic Minimed, Inc. Ranking and switching of wireless channels in a body area network of medical devices
EP2525848B1 (en) 2010-01-22 2016-08-03 DEKA Products Limited Partnership System for shape-memory alloy wire control
EP2558970A4 (en) * 2010-01-22 2013-11-06 Abbott Diabetes Care Inc Method, device and system for providing analyte sensor calibration
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
US20120259184A1 (en) * 2010-02-18 2012-10-11 Richard Abdallah Blood glucose measurement device
EP2897068B1 (en) * 2010-02-25 2020-01-01 Lifescan Scotland Limited Analyte testing method and system with high and low blood glucose trends notification
WO2011112753A1 (en) 2010-03-10 2011-09-15 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
LT3766408T (en) 2010-03-24 2022-07-11 Abbott Diabetes Care, Inc. Medical device inserters
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US8206340B2 (en) 2010-08-18 2012-06-26 Thuban, Inc. Integrated glucose monitor and insulin injection pen with automatic emergency notification
EP2624745A4 (en) 2010-10-07 2018-05-23 Abbott Diabetes Care, Inc. Analyte monitoring devices and methods
US8603032B2 (en) 2010-10-15 2013-12-10 Medtronic Minimed, Inc. Medical device with membrane keypad sealing element, and related manufacturing method
US8603033B2 (en) 2010-10-15 2013-12-10 Medtronic Minimed, Inc. Medical device and related assembly having an offset element for a piezoelectric speaker
US8562565B2 (en) 2010-10-15 2013-10-22 Medtronic Minimed, Inc. Battery shock absorber for a portable medical device
US8474332B2 (en) 2010-10-20 2013-07-02 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8495918B2 (en) 2010-10-20 2013-07-30 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8479595B2 (en) 2010-10-20 2013-07-09 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8197444B1 (en) 2010-12-22 2012-06-12 Medtronic Minimed, Inc. Monitoring the seating status of a fluid reservoir in a fluid infusion device
US8469942B2 (en) 2010-12-22 2013-06-25 Medtronic Minimed, Inc. Occlusion detection for a fluid infusion device
US8690855B2 (en) * 2010-12-22 2014-04-08 Medtronic Minimed, Inc. Fluid reservoir seating procedure for a fluid infusion device
US8628510B2 (en) 2010-12-22 2014-01-14 Medtronic Minimed, Inc. Monitoring the operating health of a force sensor in a fluid infusion device
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
CN103370099B (en) 2011-02-18 2016-01-13 美敦力公司 There is the medical treatment device programmable device of adjustable support
WO2012112178A1 (en) 2011-02-18 2012-08-23 Medtronic,Inc Modular medical device programmer
US8900206B2 (en) 2011-02-22 2014-12-02 Medtronic Minimed, Inc. Pressure vented fluid reservoir for a fluid infusion device
US9463309B2 (en) 2011-02-22 2016-10-11 Medtronic Minimed, Inc. Sealing assembly and structure for a fluid infusion device having a needled fluid reservoir
US9393399B2 (en) 2011-02-22 2016-07-19 Medtronic Minimed, Inc. Sealing assembly for a fluid reservoir of a fluid infusion device
US9283318B2 (en) 2011-02-22 2016-03-15 Medtronic Minimed, Inc. Flanged sealing element and needle guide pin assembly for a fluid infusion device having a needled fluid reservoir
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US8614596B2 (en) 2011-02-28 2013-12-24 Medtronic Minimed, Inc. Systems and methods for initializing a voltage bus and medical devices incorporating same
EP3583901A3 (en) 2011-02-28 2020-01-15 Abbott Diabetes Care, Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9101305B2 (en) 2011-03-09 2015-08-11 Medtronic Minimed, Inc. Glucose sensor product and related manufacturing and packaging methods
US8564447B2 (en) 2011-03-18 2013-10-22 Medtronic Minimed, Inc. Battery life indication techniques for an electronic device
US9018893B2 (en) 2011-03-18 2015-04-28 Medtronic Minimed, Inc. Power control techniques for an electronic device
ES2847578T3 (en) 2011-04-15 2021-08-03 Dexcom Inc Advanced analyte sensor calibration and error detection
JP6407715B2 (en) * 2011-05-06 2018-10-17 ノボ・ノルデイスク・エー/エス A system for optimizing drug dosage regimes over time
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US9317653B2 (en) * 2011-07-22 2016-04-19 Sysmex Corporation Analyzer, and method for performing a measurement on a sample
US9297819B2 (en) * 2011-07-22 2016-03-29 Sysmex Corporation Hematology analyzing system and analyzer
US10514385B2 (en) 2011-07-22 2019-12-24 Sysmex Corporation Hematology analyzer, method, and system for quality control measurements
WO2013066849A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
EP2775918B1 (en) 2011-11-07 2020-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
WO2013078426A2 (en) 2011-11-25 2013-05-30 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US8790307B2 (en) 2011-12-01 2014-07-29 Picolife Technologies, Llc Drug delivery device and methods therefor
US8771229B2 (en) 2011-12-01 2014-07-08 Picolife Technologies, Llc Cartridge system for delivery of medicament
FI4056105T3 (en) 2011-12-11 2023-12-28 Abbott Diabetes Care Inc Analyte sensor devices
CN104053396B (en) 2011-12-15 2016-12-21 贝克顿·迪金森公司 For the explanation of physiological data improved and the system presented of physiological situation management information
US9610401B2 (en) 2012-01-13 2017-04-04 Medtronic Minimed, Inc. Infusion set component with modular fluid channel element
GB2499838A (en) * 2012-03-02 2013-09-04 Smartsensor Telemed Ltd Biological test device
WO2013134519A2 (en) 2012-03-07 2013-09-12 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10130759B2 (en) 2012-03-09 2018-11-20 Picolife Technologies, Llc Multi-ported drug delivery device having multi-reservoir cartridge system
US8603026B2 (en) 2012-03-20 2013-12-10 Medtronic Minimed, Inc. Dynamic pulse-width modulation motor control and medical device incorporating same
US8523803B1 (en) 2012-03-20 2013-09-03 Medtronic Minimed, Inc. Motor health monitoring and medical device incorporating same
US8603027B2 (en) 2012-03-20 2013-12-10 Medtronic Minimed, Inc. Occlusion detection using pulse-width modulation and medical device incorporating same
US9883834B2 (en) 2012-04-16 2018-02-06 Farid Amirouche Medication delivery device with multi-reservoir cartridge system and related methods of use
US20130338630A1 (en) 2012-06-07 2013-12-19 Medtronic Minimed, Inc. Diabetes therapy management system for recommending adjustments to an insulin infusion device
US9333292B2 (en) 2012-06-26 2016-05-10 Medtronic Minimed, Inc. Mechanically actuated fluid infusion device
US10245420B2 (en) 2012-06-26 2019-04-02 PicoLife Technologies Medicament distribution systems and related methods of use
US8808269B2 (en) 2012-08-21 2014-08-19 Medtronic Minimed, Inc. Reservoir plunger position monitoring and medical device incorporating same
EP2890297B1 (en) 2012-08-30 2018-04-11 Abbott Diabetes Care, Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10496797B2 (en) 2012-08-30 2019-12-03 Medtronic Minimed, Inc. Blood glucose validation for a closed-loop operating mode of an insulin infusion system
US10130767B2 (en) 2012-08-30 2018-11-20 Medtronic Minimed, Inc. Sensor model supervisor for a closed-loop insulin infusion system
US9364609B2 (en) 2012-08-30 2016-06-14 Medtronic Minimed, Inc. Insulin on board compensation for a closed-loop insulin infusion system
US9662445B2 (en) 2012-08-30 2017-05-30 Medtronic Minimed, Inc. Regulating entry into a closed-loop operating mode of an insulin infusion system
US9849239B2 (en) 2012-08-30 2017-12-26 Medtronic Minimed, Inc. Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
US9623179B2 (en) 2012-08-30 2017-04-18 Medtronic Minimed, Inc. Safeguarding techniques for a closed-loop insulin infusion system
US9878096B2 (en) 2012-08-30 2018-01-30 Medtronic Minimed, Inc. Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
EP2901153A4 (en) 2012-09-26 2016-04-27 Abbott Diabetes Care Inc Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10318915B2 (en) 2012-09-26 2019-06-11 Thuban, Inc. Healthcare system for recording and monitoring transactions of system participants
US8870818B2 (en) 2012-11-15 2014-10-28 Medtronic Minimed, Inc. Systems and methods for alignment and detection of a consumable component
US10383580B2 (en) 2012-12-31 2019-08-20 Abbott Diabetes Care Inc. Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance
US9351670B2 (en) 2012-12-31 2016-05-31 Abbott Diabetes Care Inc. Glycemic risk determination based on variability of glucose levels
US9033924B2 (en) 2013-01-18 2015-05-19 Medtronic Minimed, Inc. Systems for fluid reservoir retention
US9107994B2 (en) 2013-01-18 2015-08-18 Medtronic Minimed, Inc. Systems for fluid reservoir retention
US9522223B2 (en) 2013-01-18 2016-12-20 Medtronic Minimed, Inc. Systems for fluid reservoir retention
CA3111631C (en) 2013-01-28 2022-12-13 Smiths Medical Asd, Inc. Medication safety devices and methods
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US9308321B2 (en) 2013-02-18 2016-04-12 Medtronic Minimed, Inc. Infusion device having gear assembly initialization
US9357961B2 (en) 2013-02-22 2016-06-07 Thuban, Inc. Device for enabling patient self testing and treatment self- administration and system using the device for managing the patient's health care
EP2973370A4 (en) 2013-03-13 2016-08-17 Carefusion 303 Inc Predictive medication safety
AU2014241019A1 (en) 2013-03-13 2015-09-03 Carefusion 303, Inc. Patient-specific medication management system
US10573413B2 (en) * 2013-03-14 2020-02-25 Roche Diabetes Care, Inc. Method for the detection and handling of hypoglycemia
WO2014152034A1 (en) 2013-03-15 2014-09-25 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10010291B2 (en) 2013-03-15 2018-07-03 Abbott Diabetes Care Inc. System and method to manage diabetes based on glucose median, glucose variability, and hypoglycemic risk
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US8920381B2 (en) 2013-04-12 2014-12-30 Medtronic Minimed, Inc. Infusion set with improved bore configuration
US20150010441A1 (en) * 2013-07-02 2015-01-08 Elana M. Kahn Electronic Pregnancy Test Device
WO2015003145A1 (en) 2013-07-03 2015-01-08 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
JP6334531B2 (en) * 2013-07-08 2018-05-30 Phcホールディングス株式会社 Blood component measuring device and blood component measuring method
US9433731B2 (en) 2013-07-19 2016-09-06 Medtronic Minimed, Inc. Detecting unintentional motor motion and infusion device incorporating same
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
US9402949B2 (en) 2013-08-13 2016-08-02 Medtronic Minimed, Inc. Detecting conditions associated with medical device operations using matched filters
US9889257B2 (en) 2013-08-21 2018-02-13 Medtronic Minimed, Inc. Systems and methods for updating medical devices
US9880528B2 (en) 2013-08-21 2018-01-30 Medtronic Minimed, Inc. Medical devices and related updating methods and systems
US9259528B2 (en) 2013-08-22 2016-02-16 Medtronic Minimed, Inc. Fluid infusion device with safety coupling
US9097720B2 (en) * 2013-09-19 2015-08-04 Roche Diagnostics Operations, Inc. Displaying glucose measurements on a handheld glucose meter
US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
US9750878B2 (en) 2013-12-11 2017-09-05 Medtronic Minimed, Inc. Closed-loop control of glucose according to a predicted blood glucose trajectory
US9750877B2 (en) 2013-12-11 2017-09-05 Medtronic Minimed, Inc. Predicted time to assess and/or control a glycemic state
US10105488B2 (en) 2013-12-12 2018-10-23 Medtronic Minimed, Inc. Predictive infusion device operations and related methods and systems
US9849240B2 (en) 2013-12-12 2017-12-26 Medtronic Minimed, Inc. Data modification for predictive operations and devices incorporating same
US9694132B2 (en) 2013-12-19 2017-07-04 Medtronic Minimed, Inc. Insertion device for insertion set
WO2015102745A1 (en) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9861748B2 (en) 2014-02-06 2018-01-09 Medtronic Minimed, Inc. User-configurable closed-loop notifications and infusion systems incorporating same
US9399096B2 (en) 2014-02-06 2016-07-26 Medtronic Minimed, Inc. Automatic closed-loop control adjustments and infusion systems incorporating same
US9987422B2 (en) 2014-03-24 2018-06-05 Medtronic Minimed, Inc. Fluid infusion patch pump device with automatic startup feature
US20170185748A1 (en) 2014-03-30 2017-06-29 Abbott Diabetes Care Inc. Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems
US10001450B2 (en) 2014-04-18 2018-06-19 Medtronic Minimed, Inc. Nonlinear mapping technique for a physiological characteristic sensor
US10232113B2 (en) 2014-04-24 2019-03-19 Medtronic Minimed, Inc. Infusion devices and related methods and systems for regulating insulin on board
US9681828B2 (en) 2014-05-01 2017-06-20 Medtronic Minimed, Inc. Physiological characteristic sensors and methods for forming such sensors
US10275572B2 (en) 2014-05-01 2019-04-30 Medtronic Minimed, Inc. Detecting blockage of a reservoir cavity during a seating operation of a fluid infusion device
US10274349B2 (en) 2014-05-19 2019-04-30 Medtronic Minimed, Inc. Calibration factor adjustments for infusion devices and related methods and systems
US10152049B2 (en) 2014-05-19 2018-12-11 Medtronic Minimed, Inc. Glucose sensor health monitoring and related methods and systems
US10007765B2 (en) 2014-05-19 2018-06-26 Medtronic Minimed, Inc. Adaptive signal processing for infusion devices and related methods and systems
US9687419B2 (en) 2014-09-12 2017-06-27 Becton, Dickinson And Company Assisted medication filling and management
US20160088136A1 (en) * 2014-09-24 2016-03-24 Paolo Di Donato Smartphone Based Meter and Injector
US9839753B2 (en) 2014-09-26 2017-12-12 Medtronic Minimed, Inc. Systems for managing reservoir chamber pressure
US9833563B2 (en) 2014-09-26 2017-12-05 Medtronic Minimed, Inc. Systems for managing reservoir chamber pressure
US10279126B2 (en) 2014-10-07 2019-05-07 Medtronic Minimed, Inc. Fluid conduit assembly with gas trapping filter in the fluid flow path
AU2015339576B2 (en) 2014-10-27 2020-02-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9833564B2 (en) 2014-11-25 2017-12-05 Medtronic Minimed, Inc. Fluid conduit assembly with air venting features
US9987420B2 (en) 2014-11-26 2018-06-05 Medtronic Minimed, Inc. Systems and methods for fluid infusion device with automatic reservoir fill
US10195341B2 (en) 2014-11-26 2019-02-05 Medtronic Minimed, Inc. Systems and methods for fluid infusion device with automatic reservoir fill
US9636453B2 (en) 2014-12-04 2017-05-02 Medtronic Minimed, Inc. Advance diagnosis of infusion device operating mode viability
US9943645B2 (en) 2014-12-04 2018-04-17 Medtronic Minimed, Inc. Methods for operating mode transitions and related infusion devices and systems
US9937292B2 (en) 2014-12-09 2018-04-10 Medtronic Minimed, Inc. Systems for filling a fluid infusion device reservoir
US10265031B2 (en) 2014-12-19 2019-04-23 Medtronic Minimed, Inc. Infusion devices and related methods and systems for automatic alert clearing
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
CN111905188B (en) 2015-02-18 2022-07-22 英赛罗公司 Fluid delivery and infusion device and method of use
US10307528B2 (en) 2015-03-09 2019-06-04 Medtronic Minimed, Inc. Extensible infusion devices and related methods
US10449298B2 (en) 2015-03-26 2019-10-22 Medtronic Minimed, Inc. Fluid injection devices and related methods
US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
EP3294134B1 (en) 2015-05-14 2020-07-08 Abbott Diabetes Care Inc. Inserter system for a compact medical device and corresponding method
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
US10137243B2 (en) 2015-05-26 2018-11-27 Medtronic Minimed, Inc. Infusion devices with distributed motor control and related operating methods
US9999721B2 (en) 2015-05-26 2018-06-19 Medtronic Minimed, Inc. Error handling in infusion devices with distributed motor control and related operating methods
US10575767B2 (en) 2015-05-29 2020-03-03 Medtronic Minimed, Inc. Method for monitoring an analyte, analyte sensor and analyte monitoring apparatus
US10010668B2 (en) 2015-06-22 2018-07-03 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and a force sensor
US9879668B2 (en) 2015-06-22 2018-01-30 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and an optical sensor
US9987425B2 (en) 2015-06-22 2018-06-05 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and sensor contact elements
US9878095B2 (en) 2015-06-22 2018-01-30 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and multiple sensor contact elements
US9993594B2 (en) 2015-06-22 2018-06-12 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and rotor position sensors
WO2017011346A1 (en) 2015-07-10 2017-01-19 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
US20170053552A1 (en) 2015-08-21 2017-02-23 Medtronic Minimed, Inc. Management and prioritization of the delivery of glycemic insight messages
US10463297B2 (en) 2015-08-21 2019-11-05 Medtronic Minimed, Inc. Personalized event detection methods and related devices and systems
US10293108B2 (en) 2015-08-21 2019-05-21 Medtronic Minimed, Inc. Infusion devices and related patient ratio adjustment methods
US10201657B2 (en) 2015-08-21 2019-02-12 Medtronic Minimed, Inc. Methods for providing sensor site rotation feedback and related infusion devices and systems
US10543314B2 (en) 2015-08-21 2020-01-28 Medtronic Minimed, Inc. Personalized parameter modeling with signal calibration based on historical data
US10117992B2 (en) 2015-09-29 2018-11-06 Medtronic Minimed, Inc. Infusion devices and related rescue detection methods
US11666702B2 (en) 2015-10-19 2023-06-06 Medtronic Minimed, Inc. Medical devices and related event pattern treatment recommendation methods
US11501867B2 (en) 2015-10-19 2022-11-15 Medtronic Minimed, Inc. Medical devices and related event pattern presentation methods
US10146911B2 (en) 2015-10-23 2018-12-04 Medtronic Minimed, Inc. Medical devices and related methods and systems for data transfer
US10037722B2 (en) 2015-11-03 2018-07-31 Medtronic Minimed, Inc. Detecting breakage in a display element
US10449306B2 (en) 2015-11-25 2019-10-22 Medtronics Minimed, Inc. Systems for fluid delivery with wicking membrane
AU2016385454B2 (en) 2016-01-05 2021-12-16 Bigfoot Biomedical, Inc. Operating multi-modal medicine delivery systems
EP3374905A1 (en) 2016-01-13 2018-09-19 Bigfoot Biomedical, Inc. User interface for diabetes management system
CN112933333B (en) 2016-01-14 2023-03-28 比格福特生物医药公司 Adjusting insulin delivery rate
US10589038B2 (en) 2016-04-27 2020-03-17 Medtronic Minimed, Inc. Set connector systems for venting a fluid reservoir
US10765807B2 (en) 2016-09-23 2020-09-08 Insulet Corporation Fluid delivery device with sensor
US11097051B2 (en) 2016-11-04 2021-08-24 Medtronic Minimed, Inc. Methods and apparatus for detecting and reacting to insufficient hypoglycemia response
US10238030B2 (en) 2016-12-06 2019-03-26 Medtronic Minimed, Inc. Wireless medical device with a complementary split ring resonator arrangement for suppression of electromagnetic interference
US10272201B2 (en) 2016-12-22 2019-04-30 Medtronic Minimed, Inc. Insertion site monitoring methods and related infusion devices and systems
CA3050721A1 (en) 2017-01-23 2018-07-26 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
US10532165B2 (en) 2017-01-30 2020-01-14 Medtronic Minimed, Inc. Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device
US10500135B2 (en) 2017-01-30 2019-12-10 Medtronic Minimed, Inc. Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device
US10552580B2 (en) 2017-02-07 2020-02-04 Medtronic Minimed, Inc. Infusion system consumables and related calibration methods
US10363365B2 (en) 2017-02-07 2019-07-30 Medtronic Minimed, Inc. Infusion devices and related consumable calibration methods
US11207463B2 (en) 2017-02-21 2021-12-28 Medtronic Minimed, Inc. Apparatuses, systems, and methods for identifying an infusate in a reservoir of an infusion device
US10646649B2 (en) 2017-02-21 2020-05-12 Medtronic Minimed, Inc. Infusion devices and fluid identification apparatuses and methods
WO2018175489A1 (en) 2017-03-21 2018-09-27 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
CN111246797A (en) 2017-10-24 2020-06-05 德克斯康公司 Pre-attached analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
WO2019209963A1 (en) 2018-04-24 2019-10-31 Deka Products Limited Partnership Apparatus and system for fluid delivery
AU2019263490A1 (en) 2018-05-04 2020-11-26 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
CN112789070A (en) 2018-09-28 2021-05-11 英赛罗公司 Mode of activity of the artificial pancreas System
WO2020077223A1 (en) 2018-10-11 2020-04-16 Insulet Corporation Event detection for drug delivery system
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996928A (en) * 1975-05-28 1976-12-14 Marx Alvin J Patient vital-signs automated measuring apparatus
US4559037A (en) * 1977-12-28 1985-12-17 Siemens Aktiengesellschaft Device for the pre-programmable infusion of liquids
US4308866A (en) * 1978-11-02 1982-01-05 University Of Southern California Infusion controlling apparatus and method
US4407959A (en) * 1980-10-29 1983-10-04 Fuji Electric Co., Ltd. Blood sugar analyzing apparatus
US4420564A (en) * 1980-11-21 1983-12-13 Fuji Electric Company, Ltd. Blood sugar analyzer having fixed enzyme membrane sensor
US4552458A (en) * 1983-10-11 1985-11-12 Eastman Kodak Company Compact reflectometer

Also Published As

Publication number Publication date
US4731726A (en) 1988-03-15

Similar Documents

Publication Publication Date Title
CA1304135C (en) Patient-operated glucose monitor and diabetes management system
US5019974A (en) Diabetes management system and apparatus
US5216597A (en) Diabetes therapy management system, apparatus and method
TWI448274B (en) Method of ensuring date and time on a test meter is accurate
CA2148708C (en) Modular microprocessor-based health monitoring system
EP0814699B1 (en) External patient reference sensor
Mazze et al. Ambulatory glucose profile: representation of verified self-monitored blood glucose data
CA2498682C (en) System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
US7264591B2 (en) System and method for monitoring air flow from a person
US7134602B2 (en) Health care apparatus
US20060064325A1 (en) Health management system, activity status measusring device, and data processing device
US20060004611A1 (en) Remote health monitoring and maintenance system
US20100249566A1 (en) Interactive device for monitoring and reporting glucose levels with integrated atomic clock module
Blevins Professional continuous glucose monitoring in clinical practice 2010
WO2002005702A2 (en) Closed loop glycemic index system
WO2003032827A1 (en) Method for reliable measurement in medical care and patient self monitoring
Wysocki Impact of blood glucose monitoring on diabetic control: obstacles and interventions
Bergenstal et al. Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control
US20040059196A1 (en) Patient monitoring system for the automatic registration of restrictions on daily abilities
Tattersall et al. A critical evaluation of methods of monitoring diabetic control
US20080161667A1 (en) Interactive device for monitoring and reporting glucose levels
CN2503533Y (en) Diet nutrition planning device for glycuresis patient
Christiansen et al. Home blood glucose monitoring: benefits for the patient and educator
Gonder-Frederick et al. Patient blood glucose monitoring: Use, accuracy, adherence, and impact
CN212233399U (en) Intelligent bracelet and blood glucose measurement monitoring system

Legal Events

Date Code Title Description
MKEX Expiry